Series A: e-Books on Cardiovascular Diseases
Series A Content Consultant: Justin D Pearlman, MD, PhD, FACC
VOLUME FOUR
Regenerative and Translational Medicine
The Therapeutic Promise for
Cardiovascular Diseases
Larry H Bernstein, MD, FCAP, Senior Editor, Author and Curator
and
Aviva Lev-Ari, PhD, RN, Editor and Curator
Image Source: Google Images
Aviva Lev-Ari, PhD, RN
Editor-in-Chief BioMed e-Series of e-Books
Leaders in Pharmaceutical Business Intelligence, Boston
avivalev-ari@alum.berkeley.edu
http://www.amazon.com/dp/B019UM909A
Other e-Books in the BioMedicine e-Series
Series A: e-Books on Cardiovascular Diseases
Content Consultant: Justin D Pearlman, MD, PhD, FACC
Volume One: Perspectives on Nitric Oxide
Sr. Editor: Larry Bernstein, MD, FCAP, Editor: Aviral Vatsa, PhD and Content Consultant: Stephen J Williams, PhD
available on Kindle Store @ Amazon.com
http://www.amazon.com/dp/B00DINFFYC
Volume Two: Cardiovascular Original Research: Cases in Methodology Design for Content Co-Curation
Curators: Justin D Pearlman, MD, PhD, FACC, Larry H Bernstein, MD, FCAP, Aviva Lev-Ari, PhD, RN
- Causes
- Risks and Biomarkers
- Therapeutic Implications
Volume Three: Etiologies of CVD: Epigenetics, Genetics & Genomics
Curators: Larry H Bernstein, MD, FCAP and Aviva Lev-Ari, PhD, RN
- Causes
- Risks and Biomarkers
- Therapeutic Implications
Volume Four: Therapeutic Promise: CVD, Regenerative & Translational Medicine
Curators: Larry H Bernstein, MD, FCAP and Aviva Lev-Ari, PhD, RN
- Causes
- Risks and Biomarkers
- Therapeutic Implications
Volume Five: Pharmaco-Therapies for CVD
Volume Curators: Justin D Pearlman, MD, PhD, FACC and Aviva Lev-Ari, PhD, RN
- Causes
- Risks and Biomarkers
- Therapeutic Implications
Volume Six: Interventional Cardiology and Cardiac Surgery for Disease Diagnosis and Guidance of Treatment
Volume Curators: Justin D Pearlman, MD, PhD, FACC and Aviva Lev-Ari, PhD, RN
- Causes
- Risks and Biomarkers
- Therapeutic Implications
In addition to the Seven Volumes of SERIES A: Cardiovascular Diseases, Not included in SERIES A is a Three Volume Series by Dr. Pearlman, Editor, on Cardiovascular Diseases, positioned as Academic Textbooks for Training Residents in Cardiology and Texts for CEU Courses in Cardiology [Hardcover, Softcover, e-Books].
- CVD 1: Causes of Cardiovascular Diseases
- CVD 2: Risk Assessment of Cardiovascular Diseases
- CVD 3: Management of Cardiovascular Diseases
- CVD 4: Volume Seven: Cardiac Imaging
Series B: e-Books on Genomics & Medicine
Content Consultant: Larry H Bernstein, MD, FCAP
Volume 1: Genomics and Individualized Medicine
Sr. Editor: Stephen J Williams, PhD
Editors: Larry H Bernstein, MD, FCAP and Aviva Lev-Ari, PhD, RN
Volume 2: Latest in Genomics Methodologies for Therapeutics: Gene Editing, NGS & BioInformatics, Simulations and the Genome Ontology
Editors: Stephen J Williams, PhD and TBA
Volume 3: Institutional Leadership in Genomics
Editors: Aviva Lev-Ari, PhD, RN and TBA
Series C: e-Books on Cancer & Oncology
Content Consultant: Larry H Bernstein, MD, FCAP
Volume 1: Cancer and Genomics
Sr. Editor: Stephen J Williams, PhD
Editors: Ritu Saxena, PhD, Tilda Barliya, PhD
Volume 2: Cancer Therapies: Metabolic, Genomics, Interventional, Immunotherapy and Nanotechnology in Therapy Delivery
Author, Curator and Editor: Larry H Bernstein, MD, FCAP
Guest Authors: Stephen J Williams, PhD, Dror Nir, PhD and Tilda Barliya, PhD, Demet Sag, PhD
Volume 3: Cancer Patients’ Resources on Therapies
Sr. Editor: TBA
Series D: e-Books on BioMedicine
Content Consultant: Larry H Bernstein, MD, FCAP
Volume 1: Metabolic Genomics & Pharmaceutics
Author, Curator and Editor: Larry H Bernstein, MD, FCAP
Volume 2: Infectious Diseases
Editor: TBA
Volume 3: Immunology and Therapeutics
Author, Curator and Editor: Larry H Bernstein, MD, FCAP
Series E: Patient-centered Medicine
Content Consultant: Larry H Bernstein, MD, FCAP
Volume 1: The VOICES of Patients, HealthCare Providers, Care Givers and Families: Personal Experience with Critical Care and Invasive Medical Procedures
Author, Curator and Editor: Larry H Bernstein, MD, FCAP
Volume 2: Medical Scientific Discoveries for the 21st Century & Interviews with Scientific Leaders
Author, Curator and Editor: Larry H Bernstein, MD, FCAP
Volume 3: Milestones in Physiology & Discoveries in Medicine and Genomics
Author, Curator and Editor: Larry H Bernstein, MD, FCAP
Volume 4: Medical 3D BioPrinting – The Revolution in Medicine
Our DOMAINS in Scientific Media
I. Pharmaceutical: Biologics, Small Molecules, Diagnostics
II. Life Sciences: Genomics and Cancer Biology
III. Patient-centered Medicine: Focus on #1: Cardiovascular, #2: Cancer, #3: Physiology Metabolomics, Immunology
IV. Biomedicine, BioTech, and MedTech (Medical Devices)
V. HealthCare: Patient-centered Medicine and Personalized/Precision Medicine
This e-Book
Open Access Online Journal
http://www.pharmaceuticalIntelligence.com
This is a scientific, medical and business, multi-expert authoring environment for information syndication in several domains of Life Sciences, Medicine, Pharmaceutical and Healthcare Industries, BioMedicine, Medical Technologies & Devices. Scientific critical interpretations and original articles are written by PhDs, MDs, MD/PhDs, PharmDs, Technical MBAs as Experts, Authors, Writers (EAWs) on an Equity Sharing basis.
List of Contributors
Justin D. Pearlman MD ME PhD MA FACC, Content Consultant to Series A: Cardiovascular Diseases
Part One
1.2, 4.1.6, 4.2.6
Epilogue to Volume Four
Larry H Bernstein, MD, FCAP, Volume Editor, Author and Article Curator
Epilogue to Volume Four
Aviva Lev-Ari, PhD, RN, Volume Editor, Article Curator, Editor-in-Chief, BioMed e-Series
Ritu Saxena, PhD, Article Author & Curator
Sudipta Saha, PhD, Article Curator
Dr. Demet Sag, Article Author & Curator
Dr. Stephen J Williams, Article Author & Curator
Part One:
2.2.8, 2.6.4, 2.7.6
Dr. Margaret Baker, Article Author & Curator
LIST of VIDEOS
Insert HERE list
electronic Table of Contents (eTOCs)
Part One:
Cardiovascular Diseases,Translational Medicine (TM) and Post TM
Introduction to Part 1: Cardiovascular Diseases,Translational Medicine (TM) and Post TM
Chapter 1: Translational Medicine Concepts
1.0 Post-Translational Modification of Proteins
1.1 Identifying Translational Science within the Triangle of Biomedicine
1.2 State of Cardiology on Wall Stress, Ventricular Workload and Myocardial Contractile Reserve: Aspects of Translational Medicine (TM)
1.3 Risk of Bias in Translational Science
1.4 Biosimilars: Intellectual Property Creation and Protection by Pioneer and by Biosimilar Manufacturers
Chapter 2: Causes and the Etiology of Cardiovascular Diseases: Translational Approaches for Cardiothoracic Medicine
2.1 Genomics
2.1.1 Genomics-Based Classification
2.1.2 Targeting Untargetable Proto-Oncogenes
2.1.3 Searchable Genome for Drug Development
2.1.4 Zebrafish Study Tool
2.1.5 International Human Genome Sequencing Consortium (2004) Finishing the euchromatic sequence of the human genome.
2.2 Proteomics
2.2.1 The Role of Tight Junction Proteins in Water and Electrolyte Transport
2.2.2 Selective Ion Conduction
2.2.3 Translational Research on the Mechanism of Water and Electrolyte Movements into the Cell
2.2.4 Inhibition of the Cardiomyocyte-Specific Kinase TNNI3K Oxidative Stress
2.2.5 Oxidized Calcium Calmodulin Kinase and Atrial Fibrillation
2.2.6 S-Nitrosylation in Cardiac Ischemia and Acute Coronary Syndrome
2.2.7 Acetylation and Deacetylation
2.2.8 Nitric Oxide Synthase Inhibitors (NOS-I)
2.3 Cardiac and Vascular Signaling
2.3.1 The Centrality of Ca(2+) Signaling and Cytoskeleton Involving Calmodulin Kinases and Ryanodine Receptors in Cardiac Failure, Arterial Smooth Muscle, Post-ischemic Arrhythmia, Similarities and Differences, and Pharmaceutical Targets
2.3.2 Leptin Signaling in Mediating the Cardiac Hypertrophy associated with Obesity
2.3.3 Triggering of Plaque Disruption and Arterial Thrombosis
2.3.4 Sensors and Signaling in Oxidative Stress
2.3.5 Resistance to Receptor of Tyrosine Kinase
2.3.6 S-nitrosylation signaling in cell biology.
2.4 Platelet Endothelial Interaction
2.4.1 Platelets in Translational Research 1
2.4.2 Platelets in Translational Research 2: Discovery of Potential Anti-platelet Targets
2.4.3 The Final Considerations of the Role of Platelets and Platelet Endothelial Reactions in Atherosclerosis and Novel Treatments
2.4.4 Endothelial Function and Cardiovascular Disease Larry H Bernstein, MD, FCAP
2.5 Post-translational modifications (PTMs)
2.5.1 Post-Translational Modifications
2.5.2. Analysis of S-nitrosylated Proteins
2.5.3 Mechanisms of Disease: Signal Transduction: Akt Phosphorylates HK-II at Thr-473 and Increases Mitochondrial HK-II Association to Protect Cardiomyocytes
2.5.4 Acetylation and Deacetylation of non-Histone Proteins
2.5.5 Study Finds Low Methylation Regions Prone to Structural Mutation
2.6 Epigenetics and lncRNAs
2.6.1 The Magic of the Pandora’s Box : Epigenetics and Stemness with Long non-coding RNAs (lincRNA)
2.6.2 The SILENCE of the Lambs” Introducing The Power of Uncoded RNA
2.6.3 Long Noncoding RNA Network regulates PTEN Transcription
2.6.4 How mobile elements in “Junk” DNA promote cancer. Part 1: Transposon-mediated tumorigenesis.
2.6.5 Transposon-mediated Gene Therapy improves Pulmonary Hemodynamics and attenuates Right Ventricular Hypertrophy: eNOS gene therapy reduces Pulmonary vascular remodeling and Arterial wall hyperplasia
2.6.6 Junk DNA codes for valuable miRNAs: non-coding DNA controls Diabetes
2.6.7 Targeted Nucleases
2.6.8 Late Onset of Alzheimer’s Disease and One-carbon Metabolism Dr. Sudipta Saha
2.6.9 Amyloidosis with Cardiomyopathy
2.6.10 Long non-coding RNAs: Molecular Regulators of Cell Fate
2.7 Metabolomics
2.7.1 Expanding the Genetic Alphabet and Linking the Genome to the Metabolome
2.7.2 How Methionine Imbalance with Sulfur-Insufficiency Leads to Hyperhomocysteinemia
2.7.3 A Second Look at the Transthyretin Nutrition Inflammatory Conundrum
2.7.4 Transthyretin and Lean Body Mass in Stable and Stressed State
2.7.5 Hyperhomocysteinemia interaction with Protein C and Increased Thrombotic Risk
2.7.6 Telling NO to Cardiac Risk
2.8 Mitochondria and Oxidative Stress
2.8.1 Reversal of Cardiac Mitochondrial Dysfunction
2.8.2 Calcium Signaling, Cardiac Mitochondria and Metabolic Syndrome
2.8.3. Mitochondrial Dysfunction and Cardiac Disorders
2.8.4 Mitochondrial Metabolism and Cardiac Function
2.8.5 Mitochondria and Cardiovascular Disease: A Tribute to Richard Bing
2.8.6 MIT Scientists on Proteomics: All the Proteins in the Mitochondrial Matrix Identified
2.8.7 Mitochondrial Dynamics and Cardiovascular Diseases
2.8.8 Mitochondrial Damage and Repair under Oxidative Stress
2.8.9 Nitric Oxide has a Ubiquitous Role in the Regulation of Glycolysis -with a Concomitant Influence on Mitochondrial Function
2.8.10 Mitochondrial Mechanisms of Disease in Diabetes Mellitus
2.8.11 Mitochondria Dysfunction and Cardiovascular Disease – Mitochondria: More than just the “Powerhouse of the Cell”
Chapter 3: Risks and Biomarkers for Diagnosis and Prognosis in Translational Cardiothoracic Medicine
3.1 Biomarkers. Diagnosis and Management: Biomarkers. Present and Future.
3.2 Landscape of Cardiac Biomarkers for Improved Clinical Utilization
3.3 Achieving Automation in Serology: A New Frontier in Best
3.4 Accurate Identification and Treatment of Emergent Cardiac Events
3.5 Prognostic Marker Importance of Troponin I in Acute Decompensated Heart Failure (ADHF)
3.6 High-Sensitivity Cardiac Troponin Assays Preparing the United States for High-Sensitivity Cardiac Troponin Assays
3.7 Voices from the Cleveland Clinic On Circulating apoA1: A Biomarker for a Proatherogenic Process in the Artery Wall
3.8 Triggering of Plaque Disruption and Arterial Thrombosis
3.9 Relationship between Adiposity and High Fructose Intake Revealed
3.10 The Cardio-Renal Syndrome (CRS) in Heart Failure (HF)
3.11 Aneuploidy and Carcinogenesis
3.12 “Sudden Cardiac Death,” SudD is in Ferrer inCode’s Suite of Cardiovascular Genetic Tests to be Commercialized in the US
Chapter 4: Therapeutic Aspects in Translational Cardiothoracic Medicine
4.1 Molecular and Cellular Cardiology
4.1.1 αllbβ3 Antagonists As An Example of Translational Medicine Therapeutics
4.1.2 Three-Dimensional Fibroblast Matrix Improves Left Ventricular Function post MI
4.1.3 Biomaterials Technology: Models of Tissue Engineering for Reperfusion and Implantable Devices for Revascularization
4.1.4 CELLWAVE Randomized Clinical Trial: Modest improvement in LVEF at 4 months “Shock wavefacilitated intracoronary administration of BMCs” vs “Shock wave treatment alone”
4.1.5 Prostacyclin and Nitric Oxide: Adventures in vascular biology – a tale of two mediators
4.1.6 Cardiac Contractility & Myocardium Performance: Ventricular Arrhythmias and Non-ischemic Heart Failure – Therapeutic Implications for Cardiomyocyte Ryanopathy
4.1.7 Publications on Heart Failure by Prof. William Gregory Stevenson, M.D., BWH
4.2 Interventional Cardiology and Cardiac Surgery – Mechanical Circulatory Support and Vascular Repair
4.2.1 Mechanical Circulatory Support System, LVAD, RVAD, Biventricular as a Bridge to Heart Transplantation or as “Destination Therapy”: Options for Patients in Advanced Heart Failure
4.2.2 Heart Transplantation: NHLBI’s Ten Year Strategic Research Plan to Achieving Evidence-based Outcomes
4.2.3 Improved Results for Treatment of Persistent type 2 Endoleak after Endovascular Aneurysm Repair: Onyx Glue Embolization
4.2.4 Carotid Endarterectomy (CEA) vs. Carotid Artery Stenting (CAS): Comparison of CMMS high-risk criteria on the Outcomes after Surgery: Analysis of the Society for Vascular Surgery (SVS) Vascular Registry Data
4.2.5 Effect of Hospital Characteristics on Outcomes of Endovascular Repair of Descending Aortic Aneurysms in US Medicare Population
4.2.6 Hypertension and Vascular Compliance: 2013 Thought Frontier – An Arterial Elasticity Focus
4.2.7 Preventive Medicine Philosophy: Excercise vs. Drug, IF More of the First THEN Less of the Second
4.2.8 Cardio-oncology and Onco-Cardiology Programs: Treatments for Cancer Patients with a History of Cardiovascular Disease
Summary to Part One
Part Two:
Cardiovascular Diseases and Regenerative Medicine
Introduction to Part Two
Chapter 1: Stem Cells in Cardiovascular Diseases
1.1 Regeneration: Cardiac System (cardiomyogenesis) and Vasculature (angiogenesis)
1.2 Notable Contributions to Regenerative Cardiology by Richard T. Lee (Lee’s Lab, Part I)
1.3 Contributions to Cardiomyocyte Interactions and Signaling (Lee’s Lab, Part II)
1.4 Jmjd3 and Cardiovascular Differentiation of Embryonic Stem Cells
1.5 Stem Cell Therapy for Coronary Artery Disease (CAD)
1.6 Intracoronary Transplantation of Progenitor Cells after Acute MI
1.7 Progenitor Cell Transplant for MI and Cardiogenesis (Part 1)
1.8 Source of Stem Cells to Ameliorate Damage Myocardium (Part 2)
1.9 Neoangiogenic Effect of Grafting an Acellular 3-Dimensional Collagen Scaffold Onto Myocardium (Part 3)
1.10 Transplantation of Modified Human Adipose Derived Stromal Cells Expressing VEGF165
1.11 Three-Dimensional Fibroblast Matrix Improves Left Ventricular Function Post MI
Chapter 2: Regenerative Cell and Molecular Biology
2.1 Circulating Endothelial Progenitors Cells (cEPCs) as Biomarkers
2.2 Stem Cell Research — The Frontier at the Technion in Israel
2.3 Blood vessel-generating stem cells discovered
2.4 Heart Renewal by pre-existing Cardiomyocytes: Source of New Heart Cell Growth Discovered
2.5 The Heart: Vasculature Protection – A Concept-based Pharmacological Therapy including THYMOSIN
2.6 Innovations in Bio instrumentation for Measurement of Circulating Progenetor Endothelial Cells in Human Blood.
2.7 Endothelial Differentiation and Morphogenesis of Cardiac Precursor
Chapter 3: Therapeutics Levels In Molecular Cardiology
3.1 Secrets of Your Cells: Discovering Your Body’s Inner Intelligence (Sounds True, on sale May 1, 2013) by Sondra Barrett
3.2 Human Embryonic-Derived Cardiac Progenitor Cells for Myocardial Repair
3.3 Repair using iPPCs or Stem Cells
3.3.1 Reprogramming cell in Tissue Repair
3.3.2 Heart patients’ skin cells turned into healthy heart muscle cells
3.4 Arteriogenesis and Cardiac Repair: Two Biomaterials – Injectable Thymosin beta4 and Myocardial Matrix Hydrogel
3.5 Cardiovascular Outcomes: Function of circulating Endothelial Progenitor Cells (cEPCs): Exploring Pharmaco-therapy targeted at Endogenous Augmentation of cEPCs
3.6 Calcium Cycling (ATPase Pump) in Cardiac Gene Therapy: Inhalable Gene Therapy for Pulmonary Arterial Hypertension and Percutaneous Intra-coronary Artery Infusion for Heart Failure: Contributions by Roger J. Hajjar, MD
Chapter 4: Research Proposals for Endogenous Augmentation of circulating Endothelial Progenitor Cells (cEPCs)
4.1 Peroxisome proliferator-activated receptor (PPAR-gamma) Receptors Activation: PPARγ transrepression for Angiogenesis in Cardiovascular Disease and PPARγ transactivation for Treatment of Diabetes
4.2 Clinical Trials Results for Endothelin System: Pathophysiological role in Chronic Heart Failure, Acute Coronary Syndromes and MI – Marker of Disease Severity or Genetic Determination?
4.3 Endothelin Receptors in Cardiovascular Diseases: The Role of eNOS Stimulation
4.4 Inhibition of ET-1, ETA and ETA-ETB, Induction of NO production, stimulation of eNOS and Treatment Regime with PPAR-gamma agonists (TZD): cEPCs Endogenous Augmentation for Cardiovascular Risk Reduction – A Bibliography
4.5 Positioning a Therapeutic Concept for Endogenous Augmentation of cEPCs — Therapeutic Indications for Macrovascular Disease: Coronary, Cerebrovascular and Peripheral
4.6 Endothelial Dysfunction, Diminished Availability of cEPCs, Increasing CVD Risk for Macrovascular Disease – Therapeutic Potential of cEPCs
4.7 Vascular Medicine and Biology: CLASSIFICATION OF FAST ACTING THERAPY FOR PATIENTS AT HIGH RISK FOR MACROVASCULAR EVENTS Macrovascular Disease – Therapeutic Potential of cEPCs
4.8 Cardiovascular Disease (CVD) and the Role of agent alternatives in endothelial Nitric Oxide Synthase (eNOS) Activation and Nitric Oxide Production
4.9 Resident-cell-based Therapy in Human Ischaemic Heart Disease: Evolution in the PROMISE of Thymosin beta4 for Cardiac Repair
4.10 Macrovascular Disease – Therapeutic Potential of cEPCs: Reduction Methods for CV Risk
4.11 Bystolic’s generic Nebivolol – positive effect on circulating Endothelial Proginetor Cells endogenous augmentation
4.12 Heart Vasculature – Regeneration and Protection of Coronary Artery Endothelium and Smooth Muscle: A Concept-based Pharmacological Therapy of a Combination Three Drug Regimen including THYMOSIN
Summary to Part Two
Epilogue to Volume Four
Part One
Cardiovascular Diseases,
Translational Medicine (TM) and Post TM
VIDEO: Translational Medicine: From Better Ideas to Better Health Dr. Robert M. Califf
VIDEO: What is Translational Medicine.
VIDEO: Translational Medicine Prof. Richard Aspinall
VIDEO: Biobanking and the Future of Translational Medicine.
Part 1 Part 2 Part 3 Dr. Gyorgy Marko-Varga
- Causes
- Risks and Biomarkers
- Therapeutic Implications
Introduction to Part One:
Cardiovascular Diseases,Translational Medicine (TM) and Post TM
Author and Curator: Larry H Bernstein, MD, FCAP
and
Curator: Aviva Lev-Ari, PhD, RN
This document in the Series A: Cardiovascular Diseases e-Series Volume 4: Translational and Regenerative Medicine, is a measure of the postgenomic and proteomic advances in the laboratory to the practice of clinical medicine. The Chapters are preceded by several videos by prominent figures in the emergence of this transformative change. When I was a medical student, a large body of the current language and technology that has extended the practice of medicine did not exist, but a new foundation, predicated on the principles of modern medical education set forth by Abraham Flexner, was sprouting. The highlights of this evolution were:
- Requirement for premedical education in biology, organic chemistry, physics, and genetics.
- Medical education included two years of basic science education in anatomy, physiology, pharmacology, and pathology prior to introduction into the clinical course sequence of the last two years.
- Post medical graduate education was an internship year followed by residency in pediatrics, OBGyn, internal medicine, general surgery, psychiatry, neurology, neurosurgery, pathology, radiology, and anesthesiology, emergency medicine.
- Academic teaching centers were developing subspecialty centers in ophthalmology, ENT and head and neck surgery, cardiology and cardiothoracic surgery, and hematology, hematology/oncology, and neurology.
- The expansion of postgraduate medical programs included significant postgraduate funding for programs by the National Institutes of Health, and the NIH had faculty development support in a system of peer-reviewed research grant programs in medical and allied sciences.
The period after the late 1980s saw a rapid expansion of research in genomics and drug development to treat emerging threats of infectious diseases as US had a large worldwide involvement after the end of the Vietnam War, and drug resistance was increasingly encountered (malaria, tick borne diseases, salmonellosis, pseudomonas aeruginosa, staphylococcus aureus, etc.).
Moreover, the post-millenium found a large, dwindling population of veterans who had served in WWII and Vietnam, and cardiovascular, musculoskeletal, dementias, and cancer were now more common. The Human Genome Project was undertaken to realign the existing knowledge of gene structure and genetic regulation with the needs for drug development, which was languishing in development failures due to unexpected toxicities.
A substantial disconnect existed between diagnostics and pharmaceutical development, which had been over-reliant on modification of known organic structures to increase potency and reduce toxicity. This was about to change with changes in medical curricula, changes in residency programs and physicians cross-training in disciplines, and the emergence of bio-pharma, based on the emerging knowledge of the cell function, and at the same time, the medical profession was developing an evidence-base for therapeutics, and more pressure was placed on informed decision-making.
The great improvement in proteomics came from GCLC/MS-MS and is described in the video interview with Dr. Gyorgy Marko-Varga, Sweden, in video 1 of 3 (Advancing Translational Medicine). This is a discussion that is focused on functional proteomics role in future diagnostics and therapy, involving a greater degree of accuracy in mass spectrometry (MS) than can be obtained by antibody-ligand binding, and is illustrated below, the last emphasizing the importance of information technology and predictive analytics
Thermo ScientificImmunoassays and LC–MS/MS have emerged as the two main approaches for quantifying peptides and proteins in biological samples. ELISA kits are available for quantification, but inherently lack the discriminative power to resolve isoforms and PTMs.
To address this issue we have developed and applied a mass spectrometry immunoassay–selected reaction monitoring (Thermo Scientific™ MSIA™ SRM technology) research method to quantify PCSK9 (and PTMs), a key player in the regulation of circulating low density lipoprotein cholesterol (LDL-C).
A Day in the (Future) Life of a Predictive Analytics Scientist
By Lars Rinnan, CEO, NextBridge April 22, 2014
A look into a normal day in the near future, where predictive analytics is everywhere, incorporated in everything from household appliances to wearable computing devices.
During the test drive (of an automobile), the extreme acceleration makes your heart beat so fast that your personal health data sensor triggers an alarm. The health data sensor is integrated into the strap of your wrist watch. This data is transferred to your health insurance company, so you say a prayer that their data scientists are clever enough to exclude these abnormal values from your otherwise impressive health data. Based on such data, your health insurance company’s consulting unit regularly gives you advice about diet, exercise, and sleep. You have followed their advice in the past, and your performance has increased, which automatically reduced your insurance premiums. Win-win, you think to yourself, as you park the car, and decide to buy it.
In the clinical presentation at Harlan Krumholtz’ Yale Symposium, Prof. Robert Califf, Director of the Duke University Translational medicine Clinical Research Institute, defines translational medicine as effective translation of science to clinical medicine in two segments:
- Adherence to current standards
- Improving the enterprise by translating knowledge
He says that discrepancies between outcomes and medical science will bridge a gap in translation by traversing two parallel systems.
- Physician-health organization
- Personalized medicine
He emphasizes that the new basis for physician standards will be legitimized in the following:
- Comparative effectiveness (Krumholtz)
- Accountability
Some of these points are repeated below:
WATCH VIDEOS ON YOUTUBE
https://www.youtube.com/watch?v=JFdJRh9ZPps#t=678 Harlan Krumholtz
https://www.youtube.com/watch?v=JFdJRh9ZPps#t=678 complexity
https://www.youtube.com/watch?v=JFdJRh9ZPps#t=678 integration map
https://www.youtube.com/watch?v=JFdJRh9ZPps#t=678 progression
https://www.youtube.com/watch?v=JFdJRh9ZPps#t=678 informatics
An interesting sidebar to the scientific medical advances is the huge shift in pressure on an insurance system that has coexisted with a public system in Medicare and Medicaid, initially introduced by the health insurance industry for worker benefits (Kaiser, IBM, Rockefeller), and we are undertaking a formidable change in the ACA.
The current reality is that actuarially, the twin system that has existed was unsustainable in the long term because it is necessary to have a very large pool of the population to spread the costs, and in addition, the cost of pharmaceutical development has driven consolidation in the industry, and has relied on the successes from public and privately funded research.
https://www.youtube.com/watch?v=X6J_7PvWoMw#t=57 Corbett Report Nov 2013
(1979 ER Brown) UCPress Rockefeller Medicine Men
https://www.youtube.com/watch?v=X6J_7PvWoMw#t=57 Liz Fowler VP of Wellpoint (designed ACA)
I shall digress for a moment and insert a video history of DNA, that hits the high points very well, and is quite explanatory of the genomic revolution in medical science, biology, infectious disease and microbial antibiotic resistance, virology, stem cell biology, and the undeniability of evolution.
DNA History
https://www.youtube.com/watch?v=UUDzN4w8mKI&list=UUoHRSQ0ahscV14hlmPabkVQ
As I have noted above, genomics is necessary, but not sufficient. The story began as replication of the genetic code, which accounted for variation, but the accounting for regulation of the cell and for metabolic processes was, and remains in the domain of an essential library of proteins. Moreover, the functional activity of proteins, at least but not only if they are catalytic, shows structural variants that is characterized by small differences in some amino acids that allow for separation by net charge and have an effect on protein-protein and other interactions.
Protein chemistry is so different from DNA chemistry that it is quite safe to consider that DNA in the nucleotide sequence does no more than establish the order of amino acids in proteins. On the other hand, proteins that we know so little about their function and regulation, do everything that matters including to set what and when to read something in the DNA.
Jose Eduardo de Salles Roselino, MD
Chapters 2, 3, and 4 sequentially examine:
- The causes and etiologies of cardiovascular diseases
- The diagnosis, prognosis and risks determined by – biomarkers in serum, circulating cells, and solid tissue by contrast radiography
- Treatment of cardiovascular diseases by translation of science from bench to bedside, including interventional cardiology and surgical repair
These are systematically examined within a framework of:
- Genomics
- Proteomics
- Cardiac and Vascular Signaling
- Platelet and Endothelial Signaling
- Cell-protein interactions
- Protein-protein interactions
- Post-Translational Modifications (PTMs)
- Epigenetics
- Noncoding RNAs and regulatory considerations
- Metabolomics (the metabolome)
- Mitochondria and oxidative stress
Chapter 1: Translational Medicine Concepts
1.0 Post-Translational Modification of Proteins
Larry H Bernstein, MD, FCAP
1.1 Identifying Translational Science within the Triangle of Biomedicine
Griffin M Weber, Journal of Translational Medicine 2013, 11:126 (24 May 2013)
1.2 State of Cardiology on Wall Stress, Ventricular Workload and Myocardial Contractile Reserve: Aspects of Translational Medicine (TM)
Justin Pearlman, MD, PhD, FACC and Aviva Lev-Ari, PhD, RN
1.3 Risk of Bias in Translational Science
Larry H Bernstein, MD, FCAP
1.4 Biosimilars: Intellectual Property Creation and Protection by Pioneer and by Biosimilar Manufacturers
Aviva Lev-Ari, PhD, RN
Chapter 2: Causes and the Etiology of Cardiovascular Diseases – Translational Approaches for Cardiothoracic Medicine
2.1 Genomics
2.1.1 Genomics-Based Classification
Larry H Bernstein, MD, FCAP and Aviva Lev-Ari, PhD, RN
2.1.2 Targeting Untargetable Proto-Oncogenes
Larry H Bernstein, MD, FCAP and Aviva Lev-Ari, PhD, RN
2.1.3 Searchable Genome for Drug Development
Larry H Bernstein, MD, FCAP and Aviva Lev-Ari, PhD, RN
2.1.4 Zebrafish Study Tool
Larry H Bernstein, MD, FCAP and Aviva Lev-Ari, PhD, RN
2.1.5 What comes after finishing the Euchromatic Sequence of the Human Genome?
Larry H Bernstein, MD, FCAP
2.2 Proteomics
2.2.1 The Role of Tight Junction Proteins in Water and Electrolyte Transport
Larry H Bernstein, MD, FCAP
2.2.2 Selective Ion Conduction
Larry H Bernstein, MD, FCAP
2.2.3 Translational Research on the Mechanism of Water and Electrolyte Movements into the Cell
Larry H. Bernstein, MD, FACP
2.2.4 Inhibition of the Cardiomyocyte-Specific Kinase TNNI3K Oxidative Stress
Larry H Bernstein, MD, FCAP
A cardiomyocyte-specific kinase limits reperfusion injury
2.2.5 Oxidized Calcium Calmodulin Kinase and Atrial Fibrillation
Larry H. Bernstein, MD, FCAP and Aviva Lev-Ari, PhD, RN
Role of G-protein-coupled receptor with S-nitrosylation in acute coronary syndrome
2.2.6 S-Nitrosylation in Cardiac Ischemia and Acute Coronary Syndrome
2.2.6.1 S-nitrosylation signaling
Larry H Bernstein, MD, FCAP
2.2.7 Acetylation and Deacetylation
2.2.7.1 Transcriptional Silencing and Longevity Protein Sir2 histone deacetylase.
Larry H Bernstein, MD, FCAP
2.2.7.2 Acetylation and Deacetylation of non-Histone Proteins
Larry H Bernstein, MD, FCAP
2.2.8 Nitric Oxide Synthase Inhibitors (NOS-I)
Larry H Bernstein, MD, FCAP, Stephen J. Williams, PhD and Aviva Lev-Ari, PhD, RN
Comparison of inhibitor-bound crystal structures between the bacterial NOS and mammalian NOS revealed an unprecedented mode of binding to the bacterial NOS that can be further exploited for future structure-based drug design.
2.3 Cardiac and Vascular Signaling
Larry H Bernstein, MD, FCAP and Aviva Lev-Ari, PhD, RN
2.3.2 Leptin Signaling in Mediating the Cardiac Hypertrophy associated with Obesity
Larry H Bernstein, MD, FCAP and Aviva Lev-Ari, PhD, RN
2.3.3 Triggering of Plaque Disruption and Arterial Thrombosis
Larry H Bernstein, MD, FCAP
2.3.4 Sensors and Signaling in Oxidative Stress
Larry H. Bernstein, MD, FCAP
2.3.5 Resistance to Receptor of Tyrosine Kinase
Larry H. Bernstein, MD, FCAP and Aviva Lev-Ari, PhD, RN
2.3.6 Gaston B. M. et al. (2003) S-nitrosylation signaling in cell biology. Mol Interv. 3, 253-63.
2.4 Platelet Endothelial Interaction
2.4.1 Platelets in Translational Research – Part 1
Larry H Bernstein, MD, FCAP
2.4.2 Platelets in Translational Research 2: Discovery of Potential Anti-platelet Targets
Larry H. Bernstein, MD, FCAP
Larry H. Bernstein, MD, FCAP
The emergence of novel antiplatelet medications has come as a result of research-based knowledge about platelet function, about endothelial-platelet interactions, about platelet induced protein synthesis, and about cell receptors as targets of therapy.
2.4.4 Endothelial Function and Cardiovascular Disease
Larry H Bernstein, MD, FCAP
2.5 Post-translational modifications (PTMs)
2.5.1 Post-Translational Modifications
Larry H Bernstein, MD, FCAP
2.5.2. Analysis of S-nitrosylated Proteins
Larry H Bernstein, MD, FCAP
Larry H Bernstein, MD, FACP
2.5.4 Acetylation and Deacetylation of non-Histone Proteins
Larry H Bernstein, MD, FCAP
2.5.5 Study Finds Low Methylation Regions Prone to Structural Mutation
2.6 Epigenetics and Long n0n-coding RNAs (lncRNAs)
2.6.1 The Magic of the Pandora’s Box : Epigenetics and Stemness with Long non-coding RNAs (lincRNA)
Demet Sag, Ph.D., CRA, GCP
2.6.2 “The SILENCE of the Lambs” Introducing The Power of Uncoded RNA
Demet Sag, Ph.D., CRA, GCP
2.6.3 Long Noncoding RNA Network regulates PTEN Transcription
Larry H Bernstein, MD, FACP
2.6.4 How Mobile Elements in “Junk” DNA Promote Cancer – Part 1: Transposon-mediated Tumorigenesis
Stephen J. Williams, Ph.D.
Aviva Lev-Ari, PhD, RN
2.6.6 Junk DNA codes for valuable miRNAs: non-coding DNA controls Diabetes
Margaret Baker, PhD, Registered Patent Agent
2.6.7 Targeted Nucleases
Larry H Bernstein, MD, FACP
2.6.8 Late Onset of Alzheimer’s Disease and One-carbon Metabolism
Dr. Sudipta Saha
2.6.9 Amyloidosis with Cardiomyopathy
Larry H Bernstein, MD, FACP
2.6.10 Long non-coding RNAs: Molecular Regulators of Cell Fate – Lecture by Prof. Laurie Boyer @MIT – Summer Symposium 2014: RNA Biology, Cancer and Therapeutic Implications, June 13, 2014, Koch Institute @MIT http://ki.mit.edu/news/symposium
2.7 Metabolomics
2.7.1 Expanding the Genetic Alphabet and Linking the Genome to the Metabolome
Larry Bernstein, MD, FCAP
2.7.2 How Methionine Imbalance with Sulfur-Insufficiency Leads to Hyperhomocysteinemia
Larry H Bernstein, MD, FACP
2.7.3 A Second Look at the Transthyretin Nutrition Inflammatory Conundrum
Larry H. Bernstein, MD, FACP
2.7.4 Transthyretin and Lean Body Mass in Stable and Stressed State
Larry Bernstein, MD, FCAP
2.7.5 Hyperhomocysteinemia interaction with Protein C and Increased Thrombotic Risk
Larry H Bernstein, MD, FCAP
2.7.6 Telling NO to Cardiac Risk
Stephen J. Williams, PhD
2.8 Mitochondria and Oxidative Stress
2.8.1 Reversal of Cardiac Mitochondrial Dysfunction
Larry H. Bernstein, MD, FCAP
2.8.2 Calcium Signaling, Cardiac Mitochondria and Metabolic Syndrome
Larry H. Bernstein, MD, FCAP and Aviva Lev-Ari, PhD, RN
2.8.3. Mitochondrial Dysfunction and Cardiac Disorders
Larry H. Bernstein, MD, FCAP
2.8.4 Mitochondrial Metabolism and Cardiac Function
Larry H. Bernstein, MD, FCAP
2.8.5 Mitochondria and Cardiovascular Disease: A Tribute to Richard Bing
Larry H. Bernstein, MD, FCAP
2.8.6 MIT Scientists on Proteomics: All the Proteins in the Mitochondrial Matrix Identified
Aviva Lev-Ari, PhD, RN
2.8.7 Mitochondrial Dynamics and Cardiovascular Diseases
Ritu Saxena, Ph.D.
2.8.8 Mitochondrial Damage and Repair under Oxidative Stress
Larry H Bernstein, MD, FCAP
Larry H. Bernstein, MD, FACP
2.8.10 Mitochondrial Mechanisms of Disease in Diabetes Mellitus
Aviva Lev-Ari, PhD, RN
Ritu Saxena, PhD
Chapter 3: Risks and Biomarkers for Diagnosis and Prognosis in Translational Cardiothoracic Medicine
3.1 Biomarkers, Diagnosis and Management: Biomarkers, Present and Future
Larry Bernstein, MD, FCAP
3.2 Landscape of Cardiac Biomarkers for Improved Clinical Utilization
Larry H Bernstein, MD, FCAP
3.3 Achieving Automation in Serology: A New Frontier in Best Practices
Larry H Bernstein, MD, FCAP
3.4 Accurate Identification and Treatment of Emergent Cardiac Events
Larry Bernstein, MD, FCAP
3.5 Prognostic Marker Importance of Troponin I in Acute Decompensated Heart Failure (ADHF)
Larry H Bernstein, MD, FCAP
3.6 High-Sensitivity Cardiac Troponin Assays Preparing the United States for High-Sensitivity Cardiac Troponin Assays
Larry Bernstein, MD, FCAP
3.7 Voices from the Cleveland Clinic On Circulating apoA1: A Biomarker for a Proatherogenic Process in the Artery Wall
Aviva Lev-Ari, PhD, RN
3.8 Triggering of Plaque Disruption and Arterial Thrombosis
Larry H Bernstein, MD, FCAP
3.9 Relationship between Adiposity and High Fructose Intake Revealed
Larry Bernstein, MD, FCAP
3.10 The Cardio-Renal Syndrome (CRS) in Heart Failure (HF)
Larry H. Bernstein, MD, FCAP and Aviva Lev-Ari, PhD, RN
3.11 Aneuploidy and Carcinogenesis
Larry H. Bernstein, MD, FCAP and Aviva Lev-Ari, PhD, RN
3.12 “Sudden Cardiac Death,” SudD is in Ferrer inCode’s Suite of Cardiovascular Genetic Tests to be Commercialized in the US
Aviva Lev-Ari, PhD, RN
Chapter 4: Therapeutic Aspects in Translational Cardiothoracic Medicine
4.1 Molecular and Cellular Cardiology
4.1.1 αllbβ3 Antagonists As An Example of Translational Medicine Therapeutics
Larry H Bernstein, MD, FCAP
4.1.2 Three-Dimensional Fibroblast Matrix Improves Left Ventricular Function post MI
Larry H. Bernstein, MD. FCAP and Aviva Lev-Ari, PhD, RN
Larry H Bernstein, MD, FACP and Aviva Lev-Ari, PhD, RN
Aviva Lev-Ari, PhD, RN
4.1.5 Prostacyclin and Nitric Oxide: Adventures in Vascular Biology – a Tale of Two Mediators
Aviva Lev-Ari, PhD, RN
Justin Pearlman, MD, PhD, FACC, Larry H Bernstein, MD, FCAP and Aviva Lev-Ari, PhD, RN
4.1.7 Publications on Heart Failure by Prof. William Gregory Stevenson, M.D., BWH
Aviva Lev-Ari, PhD, RN
4.2 Interventional Cardiology and Cardiac Surgery – Mechanical Circulatory Support and Vascular Repair
Larry H. Bernstein, MD, FACP
4.2.2 Heart Transplantation: NHLBI’s Ten Year Strategic Research Plan to Achieving Evidence-based Outcomes
Larry H. Bernstein, MD, FCAP and Aviva Lev-Ari, PhD, RN
Larry H. Bernstein, MD, FCAP and Aviva Lev-Ari, PhD, RN
Larry H. Bernstein, MD, FCAP and Aviva Lev-Ari, PhD, RN
Larry H. Bernstein, MD, FCAP and Aviva Lev-Ari, PhD, RN
4.2.6 Hypertension and Vascular Compliance: 2013 Thought Frontier – An Arterial Elasticity Focus
Justin D. Pearlman, MD, PhD, FACC and Aviva Lev-Ari, PhD, RN
4.2.7 Preventive Medicine Philosophy: Excercise vs. Drug, IF More of the First THEN Less of the Second
Aviva Lev-Ari, PhD, RN
Aviva Lev-Ari, PhD, RN
Summary
Translational Medicine – e-Series A: Cardiovascular Diseases
Volume Four – Part 1
Author and Curator: Larry H Bernstein, MD, FCAP
and
Curator: Aviva Lev-Ari, PhD, RN
Part 1 of Volume 4 in the e-series A: Cardiovascular Diseases and Translational Medicine, provides a foundation for grasping a rapidly developing surging scientific endeavor that is transcending laboratory hypothesis testing and providing guidelines to:
- Target genomes and multiple nucleotide sequences involved in either coding or in regulation that might have an impact on complex diseases, not necessarily genetic in nature.
- Target signaling pathways that are demonstrably maladjusted, activated or suppressed in many common and complex diseases, or in their progression.
- Enable a reduction in failure due to toxicities in the later stages of clinical drug trials as a result of this science-based understanding.
- Enable a reduction in complications from the improvement of machanical devices that have already had an impact on the practice of interventional procedures in cardiology, cardiac surgery, and radiological imaging, as well as improving laboratory diagnostics at the molecular level.
- Enable the discovery of new drugs in the continuing emergence of drug resistance.
- Enable the construction of critical pathways and better guidelines for patient management based on population outcomes data, that will be critically dependent on computational methods and large data-bases.
What has been presented can be essentially viewed in the following Table:
There are some developments that deserve additional development:
1. The importance of mitochondrial function in the activity state of the mitochondria in cellular work (combustion) is understood, and impairments of function are identified in diseases of muscle, cardiac contraction, nerve conduction, ion transport, water balance, and the cytoskeleton – beyond the disordered metabolism in cancer. A more detailed explanation of the energetics that was elucidated based on the electron transport chain might also be in order.
2. The processes that are enabling a more full application of technology to a host of problems in the environment we live in and in disease modification is growing rapidly, and will change the face of medicine and its allied health sciences.
Electron Transport and Bioenergetics
Deferred for metabolomics topic
Synthetic Biology
Introduction to Synthetic Biology and Metabolic Engineering
Kristala L. J. Prather: Part-1 <iBiology > iBioSeminars > Biophysics & Chemical Biology >
http://www.ibiology.org Lecturers generously donate their time to prepare these lectures. The project is funded by NSF and NIGMS, and is supported by the ASCB and HHMI.
Dr. Prather explains that synthetic biology involves applying engineering principles to biological systems to build “biological machines”.
Prather 1: Synthetic Biology and Metabolic Engineering 2/6/14IntroductionLecture Overview In the first part of her lecture, Dr. Prather explains that synthetic biology involves applying engineering principles to biological systems to build “biological machines”. The key material in building these machines is synthetic DNA. Synthetic DNA can be added in different combinations to biological hosts, such as bacteria, turning them into chemical factories that can produce small molecules of choice. In Part 2, Prather describes how her lab used design principles to engineer E. coli that produce glucaric acid from glucose. Glucaric acid is not naturally produced in bacteria, so Prather and her colleagues “bioprospected” enzymes from other organisms and expressed them in E. coli to build the needed enzymatic pathway. Prather walks us through the many steps of optimizing the timing, localization and levels of enzyme expression to produce the greatest yield. Speaker Bio: Kristala Jones Prather received her S.B. degree from the Massachusetts Institute of Technology and her PhD at the University of California, Berkeley both in chemical engineering. Upon graduation, Prather joined the Merck Research Labs for 4 years before returning to academia. Prather is now an Associate Professor of Chemical Engineering at MIT and an investigator with the multi-university Synthetic Biology Engineering Reseach Center (SynBERC). Her lab designs and constructs novel synthetic pathways in microorganisms converting them into tiny factories for the production of small molecules. Dr. Prather has received numerous awards both for her innovative research and for excellence in teaching. |
VIEW VIDEOS
https://www.youtube.com/watch?feature=player_embedded&v=ndThuqVumAk#t=0
https://www.youtube.com/watch?feature=player_embedded&v=ndThuqVumAk#t=12
https://www.youtube.com/watch?feature=player_embedded&v=ndThuqVumAk#t=74
https://www.youtube.com/watch?feature=player_embedded&v=ndThuqVumAk#t=129
https://www.youtube.com/watch?feature=player_embedded&v=ndThuqVumAk#t=168
https://www.youtube.com/watch?feature=player_embedded&v=ndThuqVumAk
David Bartel: micro-RNAs
I. Introduction to microRNAs
https://www.youtube.com/watch?feature=player_embedded&v=dupzE66J8u4#t=0
– See more at: http://www.ibiology.org/ibioseminars/genetics-gene-regulation/david-bartel-part-1.html#sthash.nGGr1tIt.dpuf
Calcium Cycling in Synthetic and Contractile Phasic or Tonic Vascular Smooth Muscle Cells
Current Basic and Pathological Approaches to
the Function of Muscle Cells and Tissues – From Molecules to HumansLarissa Lipskaia, Isabelle Limon, Regis Bobe and Roger Hajjar
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/48240
Calcium ions (Ca ) are present in low concentrations in the cytosol (~100 nM) and in high concentrations (in mM range) in both the extracellular medium and intracellular stores (mainly sarco/endo/plasmic reticulum, SR). This differential allows the calcium ion messenger that carries information as diverse as contraction, metabolism, apoptosis, proliferation and/or hypertrophic growth. The mechanisms responsible for generating a Ca signal greatly differ from one cell type to another.
Synthetic VSMCs have a fibroblast appearance, proliferate readily, and synthesize increased levels of various extracellular matrix components, particularly fibronectin, collagen types I and III, and tropoelastin [1]. Contractile VSMCs have a muscle-like or spindle-shaped appearance and well-developed contractile apparatus resulting from the expression and intracellular accumulation of thick and thin muscle filaments [1].
Figure 1. Schematic representation of Calcium Cycling in Contractile and Proliferating VSMCs.
Left panel: schematic representation of calcium cycling in quiescent /contractile VSMCs. Contractile re-sponse is initiated by extracellular Ca influx due to activation of Receptor Operated Ca (through phosphoinositol-coupled receptor) or to activation of L-Type Calcium channels (through an increase in luminal pressure). Small increase of cytosolic due IP3 binding to IP3R (puff) or RyR activation by LTCC or ROC-dependent Ca influx leads to large SR Ca IP3R or RyR clusters (“Ca -induced Ca SR calcium pumps (both SERCA2a and SERCA2b are expressed in quiescent VSMCs), maintaining high concentration of cytosolic Ca and setting the sensitivity of RyR or IP3R for the next spike.
Contraction of VSMCs occurs during oscillatory Ca transient.
Middle panel: schematic representa tion of atherosclerotic vessel wall. Contractile VSMC are located in the media layer, synthetic VSMC are located in sub-endothelial intima.
Right panel: schematic representation of calcium cycling in quiescent /contractile VSMCs. Agonist binding to phosphoinositol-coupled receptor leads to the activation of IP3R resulting in large increase in cytosolic Ca calcium pumps (only SERCA2b, having low turnover and low affinity to Ca depletion leads to translocation of SR Ca sensor STIM1 towards PM, resulting in extracellular Ca influx though opening of Store Operated Channel (CRAC). Resulted steady state Ca transient is critical for activation of proliferation-related transcription factors ‘NFAT).
Abbreviations: PLC – phospholipase C; PM – plasma membrane; PP2B – Ca /calmodulin-activated protein phosphatase 2B (calcineurin); ROC- receptor activated channel; IP3 – inositol-1,4,5-trisphosphate, IP3R – inositol-1,4,5- trisphosphate receptor; RyR – ryanodine receptor; NFAT – nuclear factor of activated T-lymphocytes; VSMC – vascular smooth muscle cells; SERCA – sarco(endo)plasmic reticulum Ca sarcoplasmic reticulum.
Time for New DNA Synthesis and Sequencing Cost Curves
By Rob Carlson
I’ll start with the productivity plot, as this one isn’t new. For a discussion of the substantial performance increase in sequencing compared to Moore’s Law, as well as the difficulty of finding this data, please see this post. If nothing else, keep two features of the plot in mind: 1) the consistency of the pace of Moore’s Law and 2) the inconsistency and pace of sequencing productivity. Illumina appears to be the primary driver, and beneficiary, of improvements in productivity at the moment, especially if you are looking at share prices. It looks like the recently announced NextSeq and Hiseq instruments will provide substantially higher productivities (hand waving, I would say the next datum will come in another order of magnitude higher), but I think I need a bit more data before officially putting another point on the plot.
Illumina’s instruments are now responsible for such a high percentage of sequencing output that the company is effectively setting prices for the entire industry. Illumina is being pushed by competition to increase performance, but this does not necessarily translate into lower prices. It doesn’t behoove Illumina to drop prices at this point, and we won’t see any substantial decrease until a serious competitor shows up and starts threatening Illumina’s market share. The absence of real competition is the primary reason sequencing prices have flattened out over the last couple of data points.
Note that the oligo prices above are for column-based synthesis, and that oligos synthesized on arrays are much less expensive. However, array synthesis comes with the usual caveat that the quality is generally lower, unless you are getting your DNA from Agilent, which probably means you are getting your dsDNA from Gen9.
Note also that the distinction between the price of oligos and the price of double-stranded sDNA is becoming less useful. Whether you are ordering from Life/Thermo or from your local academic facility, the cost of producing oligos is now, in most cases, independent of their length. That’s because the cost of capital (including rent, insurance, labor, etc) is now more significant than the cost of goods. Consequently, the price reflects the cost of capital rather than the cost of goods. Moreover, the cost of the columns, reagents, and shipping tubes is certainly more than the cost of the atoms in the sDNA you are ostensibly paying for. Once you get into longer oligos (substantially larger than 50-mers) this relationship breaks down and the sDNA is more expensive. But, at this point in time, most people aren’t going to use longer oligos to assemble genes unless they have a tricky job that doesn’t work using short oligos.
Looking forward, I suspect oligos aren’t going to get much cheaper unless someone sorts out how to either 1) replace the requisite human labor and thereby reduce the cost of capital, or 2) finally replace the phosphoramidite chemistry that the industry relies upon.
IDT’s gBlocks come at prices that are constant across quite substantial ranges in length. Moreover, part of the decrease in price for these products is embedded in the fact that you are buying smaller chunks of DNA that you then must assemble and integrate into your organism of choice.
Someone who has purchased and assembled an absolutely enormous amount of sDNA over the last decade, suggested that if prices fell by another order of magnitude, he could switch completely to outsourced assembly. This is a potentially interesting “tipping point”. However, what this person really needs is sDNA integrated in a particular way into a particular genome operating in a particular host. The integration and testing of the new genome in the host organism is where most of the cost is. Given the wide variety of emerging applications, and the growing array of hosts/chassis, it isn’t clear that any given technology or firm will be able to provide arbitrary synthetic sequences incorporated into arbitrary hosts.
TrackBack URL: http://www.synthesis.cc/cgi-bin/mt/mt-t.cgi/397
Startup to Strengthen Synthetic Biology and Regenerative Medicine Industries with Cutting Edge Cell Products
28 Nov 2013 | PR Web
Dr. Jon Rowley and Dr. Uplaksh Kumar, Co-Founders of RoosterBio, Inc., a newly formed biotech startup located in Frederick, are paving the way for even more innovation in the rapidly growing fields of Synthetic Biology and Regenerative Medicine. Synthetic Biology combines engineering principles with basic science to build biological products, including regenerative medicines and cellular therapies. Regenerative medicine is a broad definition for innovative medical therapies that will enable the body to repair, replace, restore and regenerate damaged or diseased cells, tissues and organs. Regenerative therapies that are in clinical trials today may enable repair of damaged heart muscle following heart attack, replacement of skin for burn victims, restoration of movement after spinal cord injury, regeneration of pancreatic tissue for insulin production in diabetics and provide new treatments for Parkinson’s and Alzheimer’s diseases, to name just a few applications.
While the potential of the field is promising, the pace of development has been slow. One main reason for this is that the living cells required for these therapies are cost-prohibitive and not supplied at volumes that support many research and product development efforts. RoosterBio will manufacture large quantities of standardized primary cells at high quality and low cost, which will quicken the pace of scientific discovery and translation to the clinic. “Our goal is to accelerate the development of products that incorporate living cells by providing abundant, affordable and high quality materials to researchers that are developing and commercializing these regenerative technologies” says Dr. Rowley
Life at the Speed of Light
http://kcpw.org/?powerpress_pinw=92027-podcast
NHMU Lecture featuring – J. Craig Venter, Ph.D.
Founder, Chairman, and CEO – J. Craig Venter Institute; Co-Founder and CEO, Synthetic Genomics Inc.
J. Craig Venter, Ph.D., is Founder, Chairman, and CEO of the J. Craig Venter Institute (JVCI), a not-for-profit, research organization dedicated to human, microbial, plant, synthetic and environmental research. He is also Co-Founder and CEO of Synthetic Genomics Inc. (SGI), a privately-held company dedicated to commercializing genomic-driven solutions to address global needs.
In 1998, Dr. Venter founded Celera Genomics to sequence the human genome using new tools and techniques he and his team developed. This research culminated with the February 2001 publication of the human genome in the journal, Science. Dr. Venter and his team at JVCI continue to blaze new trails in genomics. They have sequenced and a created a bacterial cell constructed with synthetic DNA, putting humankind at the threshold of a new phase of biological research. Whereas, we could previously read the genetic code (sequencing genomes), we can now write the genetic code for designing new species.
The science of synthetic genomics will have a profound impact on society, including new methods for chemical and energy production, human health and medical advances, clean water, and new food and nutritional products. One of the most prolific scientists of the 21st century for his numerous pioneering advances in genomics, he guides us through this emerging field, detailing its origins, current challenges, and the potential positive advances.
His work on synthetic biology truly embodies the theme of “pushing the boundaries of life.” Essentially, Venter is seeking to “write the software of life” to create microbes designed by humans rather than only through evolution. The potential benefits and risks of this new technology are enormous. It also requires us to examine, both scientifically and philosophically, the question of “What is life?”
J Craig Venter wants to digitize DNA and transmit the signal to teleport organisms
2013 Genomics: The Era Beyond the Sequencing of the Human Genome: Francis Collins, Craig Venter, Eric Lander, et al.
Human Longevity Inc (HLI) – $70M in Financing of Venter’s New Integrative Omics and Clinical Bioinformatics
Where Will the Century of Biology Lead Us?
By Randall Mayes
A technology trend analyst offers an overview of synthetic biology, its potential applications, obstacles to its development, and prospects for public approval.
- In addition to boosting the economy, synthetic biology projects currently in development could have profound implications for the future of manufacturing, sustainability, and medicine.
- Before society can fully reap the benefits of synthetic biology, however, the field requires development and faces a series of hurdles in the process. Do researchers have the scientific know-how and technical capabilities to develop the field?
Biology + Engineering = Synthetic Biology
Bioengineers aim to build synthetic biological systems using compatible standardized parts that behave predictably. Bioengineers synthesize DNA parts—oligonucleotides composed of 50–100 base pairs—which make specialized components that ultimately make a biological system. As biology becomes a true engineering discipline, bioengineers will create genomes using mass-produced modular units similar to the microelectronics and computer industries.
Currently, bioengineering projects cost millions of dollars and take years to develop products. For synthetic biology to become a Schumpeterian revolution, smaller companies will need to be able to afford to use bioengineering concepts for industrial applications. This will require standardized and automated processes.
A major challenge to developing synthetic biology is the complexity of biological systems. When bioengineers assemble synthetic parts, they must prevent cross talk between signals in other biological pathways. Until researchers better understand these undesired interactions that nature has already worked out, applications such as gene therapy will have unwanted side effects. Scientists do not fully understand the effects of environmental and developmental interaction on gene expression. Currently, bioengineers must repeatedly use trial and error to create predictable systems.
Similar to physics, synthetic biology requires the ability to model systems and quantify relationships between variables in biological systems at the molecular level.
The second major challenge to ensuring the success of synthetic biology is the development of enabling technologies. With genomes having billions of nucleotides, this requires fast, powerful, and cost-efficient computers. Moore’s law, named for Intel co-founder Gordon Moore, posits that computing power progresses at a predictable rate and that the number of components in integrated circuits doubles each year until its limits are reached. Since Moore’s prediction, computer power has increased at an exponential rate while pricing has declined.
DNA sequencers and synthesizers are necessary to identify genes and make synthetic DNA sequences. Bioengineer Robert Carlson calculated that the capabilities of DNA sequencers and synthesizers have followed a pattern similar to computing. This pattern, referred to as the Carlson Curve, projects that scientists are approaching the ability to sequence a human genome for $1,000, perhaps in 2020. Carlson calculated that the costs of reading and writing new genes and genomes are falling by a factor of two every 18–24 months. (see recent Carlson comment on requirement to read and write for a variety of limiting conditions).
Startup to Strengthen Synthetic Biology and Regenerative Medicine Industries with Cutting Edge Cell Products
Synthetic Biology: On Advanced Genome Interpretation for Gene Variants and Pathways: What is the Genetic Base of Atherosclerosis and Loss of Arterial Elasticity with Aging
Synthesizing Synthetic Biology: PLOS Collections
http://pharmaceuticalintelligence.com/2012/08/17/synthesizing-synthetic-biology-plos-collections/
Capturing ten-color ultrasharp images of synthetic DNA structures resembling numerals 0 to 9
Silencing Cancers with Synthetic siRNAs
http://pharmaceuticalintelligence.com/2013/12/09/silencing-cancers-with-synthetic-sirnas/
Genomics Now—and Beyond the Bubble
Futurists have touted the twenty-first century as the century of biology based primarily on the promise of genomics. Medical researchers aim to use variations within genes as biomarkers for diseases, personalized treatments, and drug responses. Currently, we are experiencing a genomics bubble, but with advances in understanding biological complexity and the development of enabling technologies, synthetic biology is reviving optimism in many fields, particularly medicine.
BY MICHAEL BROOKS 17 APR, 2014 http://www.newstatesman.com/
Michael Brooks holds a PhD in quantum physics. He writes a weekly science column for the New Statesman, and his most recent book is The Secret Anarchy of Science.
The basic idea is that we take an organism – a bacterium, say – and re-engineer its genome so that it does something different. You might, for instance, make it ingest carbon dioxide from the atmosphere, process it and excrete crude oil.
That project is still under construction, but others, such as using synthesised DNA for data storage, have already been achieved. As evolution has proved, DNA is an extraordinarily stable medium that can preserve information for millions of years. In 2012, the Harvard geneticist George Church proved its potential by taking a book he had written, encoding it in a synthesised strand of DNA, and then making DNA sequencing machines read it back to him.
When we first started achieving such things it was costly and time-consuming and demanded extraordinary resources, such as those available to the millionaire biologist Craig Venter. Venter’s team spent most of the past two decades and tens of millions of dollars creating the first artificial organism, nicknamed “Synthia”. Using computer programs and robots that process the necessary chemicals, the team rebuilt the genome of the bacterium Mycoplasma mycoides from scratch. They also inserted a few watermarks and puzzles into the DNA sequence, partly as an identifying measure for safety’s sake, but mostly as a publicity stunt.
What they didn’t do was redesign the genome to do anything interesting. When the synthetic genome was inserted into an eviscerated bacterial cell, the new organism behaved exactly the same as its natural counterpart. Nevertheless, that Synthia, as Venter put it at the press conference to announce the research in 2010, was “the first self-replicating species we’ve had on the planet whose parent is a computer” made it a standout achievement.
Today, however, we have entered another era in synthetic biology and Venter faces stiff competition. The Steve Jobs to Venter’s Bill Gates is Jef Boeke, who researches yeast genetics at New York University.
Boeke wanted to redesign the yeast genome so that he could strip out various parts to see what they did. Because it took a private company a year to complete just a small part of the task, at a cost of $50,000, he realised he should go open-source. By teaching an undergraduate course on how to build a genome and teaming up with institutions all over the world, he has assembled a skilled workforce that, tinkering together, has made a synthetic chromosome for baker’s yeast.
Stepping into DIYbio and Synthetic Biology at ScienceHack
Posted April 22, 2014 by Heather McGaw and Kyrie Vala-Webb
We got a crash course on genetics and protein pathways, and then set out to design and build our own pathways using both the “Genomikon: Violacein Factory” kit and Synbiota platform. With Synbiota’s software, we dragged and dropped the enzymes to create the sequence that we were then going to build out. After a process of sketching ideas, mocking up pathways, and writing hypotheses, we were ready to start building!
The night stretched long, and at midnight we were forced to vacate the school. Not quite finished, we loaded our delicate bacteria, incubator, and boxes of gloves onto the bus and headed back to complete our bacterial transformation in one of our hotel rooms. Jammed in between the beds and the mini-fridge, we heat-shocked our bacteria in the hotel ice bucket. It was a surreal moment.
While waiting for our bacteria, we held an “unconference” where we explored bioethics, security and risk related to synthetic biology, 3D printing on Mars, patterns in juggling (with live demonstration!), and even did a Google Hangout with Rob Carlson. Every few hours, we would excitedly check in on our bacteria, looking for bacterial colonies and the purple hue characteristic of violacein.
Most impressive was the wildly successful and seamless integration of a diverse set of people: in a matter of hours, we were transformed from individual experts and practitioners in assorted fields into cohesive and passionate teams of DIY biologists and science hackers. The ability of everyone to connect and learn was a powerful experience, and over the course of just one weekend we were able to challenge each other and grow.
Returning to work on Monday, we were hungry for more. We wanted to find a way to bring the excitement and energy from the weekend into the studio and into the projects we’re working on. It struck us that there are strong parallels between design and DIYbio, and we knew there was an opportunity to bring some of the scientific approaches and curiosity into our studio.
Part Two
Cardiovascular Diseases and Regenerative Medicine
Introduction to Part Two
Author: Larry H. Bernstein, MD. FCAP
and
Curator: Aviva Lev-Ari, PhD, RN
This document is entirely devoted to medical and surgical therapies that have made huge strides in
- simplification of interventional procedures,
- reduced complexity, resulting in procedures previously requiring surgery are now done, circumstances permitting, by medical intervention.
This revolution in cardiovascular interventional therapy is regenerative medicine. It is regenerative because it is largely driven by
- the introduction into the impaired vasculature of an induced pleuripotent cell, called a stem cell, although
- the level of differentiation may not be a most primitive cell line.
There is also a very closely aligned development in cell biology that extends beyond and including vascular regeneration that is called synthetic biology. These developments have occurred at an accelerated rate in the last 15 years. The methods of interventional cardiology were already well developed in the mid 1980s. This was at the peak of cardiothoracic bypass surgery.
Research on the endothelial cell,
- endothelial cell proliferation,
- shear flow in small arteries, especially at branch points, and
- endothelial-platelet interactions
led to insights about plaque formation and vessel thrombosis.
Much was learned in biomechanics about the shear flow stresses on the luminal surface of the vasculature, and there was also
- the concomitant discovery of nitric oxide,
- oxidative stress, and
- the isoenzymes of nitric oxide synthase (eNOS, iNOS, and nNOS).
It became a fundamental tenet of vascular biology that
- atherogenesis is a maladjustment to oxidative stress not only through genetic, but also
- non-genetic nutritional factors that could be related to the balance of omega (ω)-3 and omega (ω)-6 fatty acids,
- a pro-inflammatory state that elicits inflammatory cytokines, such as, interleukin-6 (IL6) and c-reactive protein(CRP),
- insulin resistance with excess carbohydrate associated with type 2 diabetes and beta (β) cell stress,
- excess trans- and saturated fats, and perhaps
- the now plausible colonic microbial population of the gastrointestinal tract (GIT).
There is also an association of abdominal adiposity,
- including the visceral peritoneum, with both T2DM and with arteriosclerotic vessel disease,
- which is presenting at a young age, and has ties to
- the effects of an adipokine, adiponectin.
Much important work has already been discussed in the domain of cardiac catheterization and research done to
- prevent atheroembolization.and beyond that,
- research done to implant an endothelial growth matrix.
Even then, dramatic work had already been done on
- the platelet structure and metabolism, and
- this has transformed our knowledge of platelet biology.
The coagulation process has been discussed in detailed in a previous document. The result was the development of a
- new class of platelet aggregation inhibitors designed to block the activation of protein on the platelet surface that
- is critical in the coagulation cascade.
In addition, the term long used to describe atherosclerosis, atheroma notwithstanding, is “hardening of the arteries”. This is particularly notable with respect to mid-size arteries and arterioles that feed the heart and kidneys. Whether it is preceded by or develops concurrently with chronic renal insufficiency and lowered glomerular filtration rate is perhaps arguable. However, there is now a body of evidence that points to
- a change in the vascular muscularis and vessel stiffness, in addition to the endothelial features already mentioned.
This has provided a basis for
- targeted pharmaceutical intervention, and
- reduction in salt intake.
So we have a group of metabolic disorders, which may alone or in combination,
- lead to and be associated with the long term effects of cardiovascular disease, including
- congestive heart failure.
This has been classically broken down into forward and backward failure,
- depending on decrease outflow through the aorta (ejection fraction), or
- decreased venous return through the vena cava,
which involves increased pulmonary vascular resistance and decreased return into the left atrium.
This also has ties to several causes, which may be cardiac or vascular. This document, as the previous, has four pats. They are broadly:
- Stem Cells in Cardiovascular Diseases
- Regenerative Cell and Molecular Biology
- Therapeutics Levels In Molecular Cardiology
- Research Proposals for Endogenous Augmentation of circulating Endothelial Progenitor Cells (cEPCs)
As in the previous section, we start with the biology of the stem cell and the degeneration in cardiovascular diseases, then proceed to regeneration, then therapeutics, and finally – proposals for augmenting therapy with circulating endogenous endothelial progenitor cells (cEPCs).
Chapter 1: Stem Cells in Cardiovascular Diseases
1.1 Regeneration: Cardiac System (cardiomyogenesis) and Vasculature (angiogenesis)
Aviva Lev-Ari, PhD, RN
1.2 Notable Contributions to Regenerative Cardiology by Richard T. Lee (Lee’s Lab, Part I)
Larry H Bernstein, MD, FCAP and Aviva Lev-Ari, PhD, RN
1.3 Contributions to Cardiomyocyte Interactions and Signaling (Lee’s Lab, Part II)
Larry H Bernstein, MD, FCAP and Aviva Lev-Ari, PhD, RN
1.4 Jmjd3 and Cardiovascular Differentiation of Embryonic Stem Cells
Larry H Bernstein, MD, FCAP and Aviva Lev-Ari, PhD, RN
1.5 Stem Cell Therapy for Coronary Artery Disease (CAD)
Larry H. Bernstein, MD, FCAP and Aviva Lev-Ari, PhD, RN
1.6 Intracoronary Transplantation of Progenitor Cells after Acute MI
Larry H. Bernstein, MD, FCAP and Aviva Lev-Ari, PhD, RN
1.7 Progenitor Cell Transplant for MI and Cardiogenesis (Part 1)
Larry H. Bernstein, MD, FCAP and Aviva Lev-Ari, PhD, RN
1.8 Source of Stem Cells to Ameliorate Damage Myocardium (Part 2)
Larry H. Bernstein, MD, FCAP and Aviva Lev-Ari, PhD, RN
1.9 Neoangiogenic Effect of Grafting an Acellular 3-Dimensional Collagen Scaffold Onto Myocardium (Part 3)
Larry H. Bernstein, MD, FCAP and Aviva Lev-Ari, PhD, RN
1.10 Transplantation of Modified Human Adipose Derived Stromal Cells Expressing VEGF165
Larry H. Bernstein, MD, FCAP and Aviva Lev-Ari, PhD, RN
1.11 Three-Dimensional Fibroblast Matrix Improves Left Ventricular Function Post MI
Larry H. Bernstein, MD, FCAP and Aviva Lev-Ari, PhD, RN
Chapter 2: Regenerative Cell and Molecular Biology
2.1 Circulating Endothelial Progenitors Cells (cEPCs) as Biomarkers
Larry H. Bernstein, MD, FCAP and Aviva Lev-Ari, PhD, RN
2.2 Stem Cell Research — The Frontier at the Technion in Israel
Aviva Lev-Ari, PhD, RN
2.3 Blood vessel-generating stem cells discovered
Ritu Saxena, PhD
2.4 Heart Renewal by pre-existing Cardiomyocytes: Source of New Heart Cell Growth Discovered
Aviva Lev-Ari, PhD, RN
2.5 The Heart: Vasculature Protection – A Concept-based Pharmacological Therapy including THYMOSIN
Aviva Lev-Ari, PhD, RN
2.6 Innovations in Bio instrumentation for Measurement of Circulating Progenetor Endothelial Cells in Human Blood.
Sudipta Saha, PhD
2.7 Endothelial Differentiation and Morphogenesis of Cardiac Precursor
Sudipta Saha, PhD
Chapter 3: Therapeutics Levels in Molecular Cardiology
3.1 Secrets of Your Cells: Discovering Your Body’s Inner Intelligence (Sounds True, on sale May 1, 2013) by Sondra Barrett
Aviva Lev-Ari, PhD, RN
3.2 Human Embryonic-Derived Cardiac Progenitor Cells for Myocardial Repair
Sudipta Saha, PhD
3.3 Repair using iPPCs or Stem Cells
3.3.1 Reprogramming cell in Tissue Repair
Larry H Bernstein, MD, FCAP
3.3.2 Heart patients’ skin cells turned into healthy heart muscle cells
Aviva Lev-Ari, PhD, RN
3.4 Arteriogenesis and Cardiac Repair: Two Biomaterials – Injectable Thymosin beta4 and Myocardial Matrix Hydrogel
Aviva Lev-Ari, PhD, RN
3.5 Cardiovascular Outcomes: Function of circulating Endothelial Progenitor Cells (cEPCs): Exploring Pharmaco-therapy targeted at Endogenous Augmentation of cEPCs
Aviva Lev-Ari, PhD, RN
3.6 Calcium Cycling (ATPase Pump) in Cardiac Gene Therapy: Inhalable Gene Therapy for Pulmonary Arterial Hypertension and Percutaneous Intra-coronary Artery Infusion for Heart Failure: Contributions by Roger J. Hajjar, MD
Aviva Lev-Ari, PhD, RN
Chapter 4: Research Proposals for Endogenous Augmentation of circulating Endothelial Progenitor Cells (cEPCs)
4.1 Peroxisome proliferator-activated receptor (PPAR-gamma) Receptors Activation: PPARγ transrepression for Angiogenesis in Cardiovascular Disease and PPARγ transactivation for Treatment of Diabetes
Aviva Lev-Ari, PhD, RN
4.2 Clinical Trials Results for Endothelin System: Pathophysiological role in Chronic Heart Failure, Acute Coronary Syndromes and MI – Marker of Disease Severity or Genetic Determination?
Aviva Lev-Ari, PhD, RN
4.3 Endothelin Receptors in Cardiovascular Diseases: The Role of eNOS Stimulation
Aviva Lev-Ari, PhD, RN
4.4 Inhibition of ET-1, ETA and ETA-ETB, Induction of NO production, stimulation of eNOS and Treatment Regime with PPAR-gamma agonists (TZD): cEPCs Endogenous Augmentation for Cardiovascular Risk Reduction – A Bibliography
Aviva Lev-Ari, PhD, RN
4.5 Positioning a Therapeutic Concept for Endogenous Augmentation of cEPCs — Therapeutic Indications for Macrovascular Disease: Coronary, Cerebrovascular and Peripheral
Aviva Lev-Ari, PhD, RN
4.6 Endothelial Dysfunction, Diminished Availability of cEPCs, Increasing CVD Risk for Macrovascular Disease – Therapeutic Potential of cEPCs
Aviva Lev-Ari, PhD, RN
4.7 Vascular Medicine and Biology: CLASSIFICATION OF FAST ACTING THERAPY FOR PATIENTS AT HIGH RISK FOR MACROVASCULAR EVENTS Macrovascular Disease – Therapeutic Potential of cEPCs
Aviva Lev-Ari, PhD, RN
4.8 Cardiovascular Disease (CVD) and the Role of agent alternatives in endothelial Nitric Oxide Synthase (eNOS) Activation and Nitric Oxide Production
Aviva Lev-Ari, PhD, RN
4.9 Resident-cell-based Therapy in Human Ischaemic Heart Disease: Evolution in the PROMISE of Thymosin beta4 for Cardiac Repair
Aviva Lev-Ari, PhD, RN
4.10 Macrovascular Disease – Therapeutic Potential of cEPCs: Reduction Methods for CV Risk
Aviva Lev-Ari, PhD, RN
4.11 Bystolic’s generic Nebivolol – positive effect on circulating Endothelial Proginetor Cells endogenous augmentation
Aviva Lev-Ari, PhD, RN
4.12 Heart Vasculature – Regeneration and Protection of Coronary Artery Endothelium and Smooth Muscle: A Concept-based Pharmacological Therapy of a Combination Three Drug Regimen including THYMOSIN
Aviva Lev-Ari, PhD, RN
Summary to Part Two
Author: Larry H. Bernstein, MD. FCAP
We have covered a large amount of material that involves
- the development,
- application, and
- validation of outcomes of medical and surgical procedures
that are based on translation of science from the laboratory to the bedside, improving the standards of medical practice at an accelerated pace in the last quarter century, and in the last decade. Encouraging enabling developments have been:
1. The establishment of national and international outcomes databases for procedures by specialist medical societies
Stent Design and Thrombosis: Bifurcation Intervention, Drug Eluting Stents (DES) and Biodegrable Stents
Aviva Lev-Ari, PhD, RN
Justin Pearlman, MD, PhD, FACC and Article Curator: Aviva Lev-Ari, PhD, RN
Mitral Valve Repair: Who is a Patient Candidate for a Non-Ablative Fully Non-Invasive Procedure?
Justin Pearlman, MD, PhD, FACC and Article Curator: Aviva Lev-Ari, PhD, RN
Justin D Pearlman, MD, PhD, FACC and Article Curator: Aviva Lev-Ari, PhD, RN
Survivals Comparison of Coronary Artery Bypass Graft (CABG) and Percutaneous Coronary Intervention (PCI) /Coronary Angioplasty
Larry H. Bernstein, MD, FCAP And Aviva Lev-Ari, PhD, RN
Revascularization: PCI, Prior History of PCI vs CABG
Aviva Lev-Ari, PhD, RN
Aviva Lev-Ari, PhD, RN
Aviva Lev-Ari, PhD, RN
and more
2. The identification of problem areas, particularly in activation of the prothrombotic pathways, infection control to an extent, and targeting of pathways leading to progression or to arrythmogenic complications
Anticoagulation genotype guided dosing
Larry H. Bernstein, MD, FCAP
Aviva Lev-Ari, PhD, RN
The Effects of Aprotinin on Endothelial Cell Coagulant Biology
Kamran Baig, MBBS, James Jaggers, MD, Jeffrey H. Lawson, MD, PhD
Aviva Lev-Ari, PhD, RN
Pharmacogenomics – A New Method for Druggability
Demet Sag, PhD
Advanced Topics in Sepsis and the Cardiovascular System at its End Stage
Larry H Bernstein, MD, FCAP
3. Development of procedures that use a safer materials in vascular management
Stent Design and Thrombosis: Bifurcation Intervention, Drug Eluting Stents (DES) and Biodegrable Stents
Aviva Lev-Ari, PhD, RN
Biomaterials Technology: Models of Tissue Engineering for Reperfusion and Implantable Devices for Revascularization
Larry H Bernstein, MD, FACP and Aviva Lev-Ari, PhD, RN
Vascular Repair: Stents and Biologically Active Implants
Larry H Bernstein, MD, FACP and Aviva Lev-Ari, RN, PhD
Larry H Bernstein, MD, FACP and Aviva Lev-Ari, PhD, RN
MedTech & Medical Devices for Cardiovascular Repair
Aviva Lev-Ari, PhD, RN
4. Discrimination of cases presenting for treatment based on qualifications for medical versus surgical intervention
Treatment Options for Left Ventricular Failure – Temporary Circulatory Support: Intra-aortic balloon pump (IABP) – Impella Recover LD/LP 5.0 and 2.5, Pump Catheters (Non-surgical) vs Bridge Therapy: Percutaneous Left Ventricular Assist Devices (pLVADs) and LVADs (Surgical)
Larry H Bernstein, MD, FCAP and Justin D Pearlman, MD, PhD, FACC
Larry H. Bernstein, MD, FCAP and Aviva Lev-Ari, PhD, RN
ACC/AHA Guidelines for Coronary Artery Bypass Graft Surgery
Aviva Lev-Ari, PhD, RN
Mitral Valve Repair: Who is a Patient Candidate for a Non-Ablative Fully Non-Invasive Procedure?
Justin Pearlman, MD, PhD, FACC and Article Curator: Aviva Lev-Ari, PhD, RN
5. This has become possible because of the advances in our knowledge of key related pathogenetic mechanisms involving gene expression and cellular regulation of complex mechanisms.
What is the key method to harness Inflammation to close the doors for many complex diseases?
Larry H Bernstein, MD, FCAP
CVD Prevention and Evaluation of Cardiovascular Imaging Modalities: Coronary Calcium Score by CT Scan Screening to justify or not the Use of Statin
Aviva Lev-Ari, PhD, RN
Pathophysiological Effects of Diabetes on Ischemic-Cardiovascular Disease and on Chronic Obstructive Pulmonary Disease (COPD)
Larry H. Bernstein, MD, FCAP
Larry H Bernstein, MD, CAP and Aviva Lev-Ari, PhD, RN
Notable Contributions to Regenerative Cardiology
Larry H Bernstein, MD, FCAP and Article Commissioner: Aviva Lev-Ari, PhD, RN
As noted in the introduction, any of the material can be found and reviewed by content, and the eTOC is to be found at
http://pharmaceuticalintelligence.com/biomed-e-books/series-a-e-books-on-cardiovascular-diseases/volume-four-therapeutic-promise-cvd-regenerative-translational-medicine/
This completes what has been presented in Part 2, Vol 4 , and supporting references for the main points that are found in the Leaders in Pharmaceutical Intelligence Cardiovascular book. Part 1 was concerned with Posttranslational Modification of Proteins, vital for understanding cellular regulation and dysregulation. Part 2 was concerned with Translational Medical Therapeutics, the efficacy of medical and surgical decisions based on bringing the knowledge gained from the laboratory, and from clinical trials into the realm opf best practice. The time for this to occur in practice in the past has been through roughly a generation of physicians. That was in part related to the busy workload of physicians, and inability to easily access specialty literature as the volume and complexity increased. This had an effect of making access of a family to a primary care provider through a lifetime less likely than the period post WWII into the 1980s.
However, the growth of knowledge has accelerated in the specialties since the 1980′s so that the use of physician referral in time became a concern about the cost of medical care. This is not the place for or a matter for discussion here. It is also true that the scientific advances and improvements in available technology have had a great impact on medical outcomes. The only unrelated issue is that of healthcare delivery, which is not up to the standard set by serial advances in therapeutics, accompanied by high cost due to development costs, marketing costs, and development of drug resistance.
I shall identify continuing developments in cardiovascular diagnostics, therapeutics, and bioengineering that is and has been emerging in the last decade.
1. Mechanisms of Disease
REPORT: Mapping the Cellular Response to Small Molecules Using Chemogenomic Fitness Signatures
Science 11 April 2014:
Vol. 344 no. 6180 pp. 208-211
http://dx.doi.org/10.1126/science.1250217
Abstract: Genome-wide characterization of the in vivo cellular response to perturbation is fundamental to understanding how cells survive stress. Identifying the proteins and pathways perturbed by small molecules affects biology and medicine by revealing the mechanisms of drug action. We used a yeast chemogenomics platform that quantifies the requirement for each gene for resistance to a compound in vivo to profile 3250 small molecules in a systematic and unbiased manner. We identified 317 compounds that specifically perturb the function of 121 genes and characterized the mechanism of specific compounds. Global analysis revealed that the cellular response to small molecules is limited and described by a network of 45 major chemogenomic signatures. Our results provide a resource for the discovery of functional interactions among genes, chemicals, and biological processes.
Yeasty HIPHOP
Laura Zahn
Sci. Signal. 15 April 2014; 7(321): ec103. http://dx.doi.org/10.1126/scisignal.2005362
In order to identify how chemical compounds target genes and affect the physiology of the cell, tests of the perturbations that occur when treated with a range of pharmacological chemicals are required. By examining the haploinsufficiency profiling (HIP) and homozygous profiling (HOP) chemogenomic platforms, Lee et al.(p. 208) analyzed the response of yeast to thousands of different small molecules, with genetic, proteomic, and bioinformatic analyses. Over 300 compounds were identified that targeted 121 genes within 45 cellular response signature networks. These networks were used to extrapolate the likely effects of related chemicals, their impact upon genetic pathways, and to identify putative gene functions
Key Heart Failure Culprit Discovered
A team of cardiovascular researchers from the Cardiovascular Research Center at Icahn School of Medicine at Mount Sinai, Sanford-Burnham Medical Research Institute, and University of California, San Diego have identified a small, but powerful, new player in thIe onset and progression of heart failure. Their findings, published in the journal Nature on March 12, also show how they successfully blocked the newly discovered culprit.
Investigators identified a tiny piece of RNA called miR-25 that blocks a gene known as SERCA2a, which regulates the flow of calcium within heart muscle cells. Decreased SERCA2a activity is one of the main causes of poor contraction of the heart and enlargement of heart muscle cells leading to heart failure.
Using a functional screening system developed by researchers at Sanford-Burnham, the research team discovered miR-25 acts pathologically in patients suffering from heart failure, delaying proper calcium uptake in heart muscle cells. According to co-lead study authors Christine Wahlquist and Dr. Agustin Rojas Muñoz, developers of the approach and researchers in Mercola’s lab at Sanford-Burnham, they used high-throughput robotics to sift through the entire genome for microRNAs involved in heart muscle dysfunction.
Subsequently, the researchers at the Cardiovascular Research Center at Icahn School of Medicine at Mount Sinai found that injecting a small piece of RNA to inhibit the effects of miR-25 dramatically halted heart failure progression in mice. In addition, it also improved their cardiac function and survival.
“In this study, we have not only identified one of the key cellular processes leading to heart failure, but have also demonstrated the therapeutic potential of blocking this process,” says co-lead study author Dr. Dongtak Jeong, a post-doctoral fellow at the Cardiovascular Research Center at Icahn School of Medicine at Mount Sinai in the laboratory of the study’s co-senior author Dr. Roger J. Hajjar.
Publication: Inhibition of miR-25 improves cardiac contractility in the failing heart.Christine Wahlquist, Dongtak Jeong, Agustin Rojas-Muñoz, Changwon Kho, Ahyoung Lee, Shinichi Mitsuyama, Alain Van Mil, Woo Jin Park, Joost P. G. Sluijter, Pieter A. F. Doevendans, Roger J. : Hajjar & Mark Mercola. Nature (March 2014) http://www.nature.com/nature/journal/vaop/ncurrent/full/nature13073.html
“Junk” DNA Tied to Heart Failure
Deep RNA Sequencing Reveals Dynamic Regulation of Myocardial Noncoding RNAs in Failing Human Heart and Remodeling With Mechanical Circulatory Support
Yang KC, Yamada KA, Patel AY, Topkara VK, George I, et al.
Circulation 2014; 129(9):1009-21.
http://dx.doi.org/10.1161/CIRCULATIONAHA.113.003863 http://circ.ahajournals.org/…/CIRCULATIONAHA.113.003863.full
The myocardial transcriptome is dynamically regulated in advanced heart failure and after LVAD support. The expression profiles of lncRNAs, but not mRNAs or miRNAs, can discriminate failing hearts of different pathologies and are markedly altered in response to LVAD support. These results suggest an important role for lncRNAs in the pathogenesis of heart failure and in reverse remodeling observed with mechanical support.
Junk DNA was long thought to have no important role in heredity or disease because it doesn’t code for proteins. But emerging research in recent years has revealed that many of these sections of the genome produce noncoding RNA molecules that still have important functions in the body. They come in a variety of forms, some more widely studied than others. Of these, about 90% are called long noncoding RNAs (lncRNAs), and exploration of their roles in health and disease is just beginning.
The Washington University group performed a comprehensive analysis of all RNA molecules expressed in the human heart. The researchers studied nonfailing hearts and failing hearts before and after patients received pump support from left ventricular assist devices (LVAD). The LVADs increased each heart’s pumping capacity while patients waited for heart transplants.
In their study, the researchers found that unlike other RNA molecules, expression patterns of long noncoding RNAs could distinguish between two major types of heart failure and between failing hearts before and after they received LVAD support.
“The myocardial transcriptome is dynamically regulated in advanced heart failure and after LVAD support. The expression profiles of lncRNAs, but not mRNAs or miRNAs, can discriminate failing hearts of different pathologies and are markedly altered in response to LVAD support,” wrote the researchers. “These results suggest an important role for lncRNAs in the pathogenesis of heart failure and in reverse remodeling observed with mechanical support.”
‘Junk’ Genome Regions Linked to Heart Failure
In a recent issue of the journal Circulation, Washington University investigators report results from the first comprehensive analysis of all RNA molecules expressed in the human heart. The researchers studied nonfailing hearts and failing hearts before and after patients received pump support from left ventricular assist devices (LVAD). The LVADs increased each heart’s pumping capacity while patients waited for heart transplants.
“We took an unbiased approach to investigating which types of RNA might be linked to heart failure,” said senior author Jeanne Nerbonne, the Alumni Endowed Professor of Molecular Biology and Pharmacology. “We were surprised to find that long noncoding RNAs stood out.
In the new study, the investigators found that unlike other RNA molecules, expression patterns of long noncoding RNAs could distinguish between two major types of heart failure and between failing hearts before and after they received LVAD support.
“We don’t know whether these changes in long noncoding RNAs are a cause or an effect of heart failure,” Nerbonne said. “But it seems likely they play some role in coordinating the regulation of multiple genes involved in heart function.”
Nerbonne pointed out that all types of RNA molecules they examined could make the obvious distinction: telling the difference between failing and nonfailing hearts. But only expression of the long noncoding RNAs was measurably different between heart failure associated with a heart attack (ischemic) and heart failure without the obvious trigger of blocked arteries (nonischemic). Similarly, only long noncoding RNAs significantly changed expression patterns after implantation of left ventricular assist devices.
Comment
Decoding the noncoding transcripts in human heart failure
Xiao XG, Touma M, Wang Y
Circulation. 2014; 129(9): 958–960, http://dx.doi.org/10.1161/CIRCULATIONAHA.114.007548
Heart failure is a complex disease with a broad spectrum of pathological features. Despite significant advancement in clinical diagnosis through improved imaging modalities and hemodynamic approaches, reliable molecular signatures for better differential diagnosis and better monitoring of heart failure progression remain elusive. The few known clinical biomarkers for heart failure, such as plasma brain natriuretic peptide and troponin, have been shown to have limited use in defining the cause or prognosis of the disease.1,2 Consequently, current clinical identification and classification of heart failure remain descriptive, mostly based on functional and morphological parameters. Therefore, defining the pathogenic mechanisms for hypertrophic versus dilated or ischemic versus nonischemic cardiomyopathies in the failing heart remain a major challenge to both basic science and clinic researchers. In recent years, mechanical circulatory support using left ventricular assist devices (LVADs) has assumed a growing role in the care of patients with end-stage heart failure.3 During the earlier years of LVAD application as a bridge to transplant, it became evident that some patients exhibit substantial recovery of ventricular function, structure, and electric properties.4 This led to the recognition that reverse remodeling is potentially an achievable therapeutic goal using LVADs. However, the underlying mechanism for the reverse remodeling in the LVAD-treated hearts is unclear, and its discovery would likely hold great promise to halt or even reverse the progression of heart failure.
Efficacy and Safety of Dabigatran Compared With Warfarin in Relation to Baseline Renal Function in Patients With Atrial Fibrillation: A RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) Trial Analysis
Circulation. 2014; 129: 951-952 http://dx.doi.org/10.1161/CIR.0000000000000022
In patients with atrial fibrillation, impaired renal function is associated with a higher risk of thromboembolic events and major bleeding. Oral anticoagulation with vitamin K antagonists reduces thromboembolic events but raises the risk of bleeding. The new oral anticoagulant dabigatran has 80% renal elimination, and its efficacy and safety might, therefore, be related to renal function. In this prespecified analysis from the Randomized Evaluation of Long-Term Anticoagulant Therapy (RELY) trial, outcomes with dabigatran versus warfarin were evaluated in relation to 4 estimates of renal function, that is, equations based on creatinine levels (Cockcroft-Gault, Modification of Diet in Renal Disease (MDRD), Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI]) and cystatin C. The rates of stroke or systemic embolism were lower with dabigatran 150 mg and similar with 110 mg twice daily irrespective of renal function. Rates of major bleeding were lower with dabigatran 110 mg and similar with 150 mg twice daily across the entire range of renal function. However, when the CKD-EPI or MDRD equations were used, there was a significantly greater relative reduction in major bleeding with both doses of dabigatran than with warfarin in patients with estimated glomerular filtration rate ≥80 mL/min. These findings show that dabigatran can be used with the same efficacy and adequate safety in patients with a wide range of renal function and that a more accurate estimate of renal function might be useful for improved tailoring of anticoagulant treatment in patients with atrial fibrillation and an increased risk of stroke.
Aldosterone Regulates MicroRNAs in the Cortical Collecting Duct to Alter Sodium Transport.
Robert S Edinger, Claudia Coronnello, Andrew J Bodnar, William A Laframboise,Panayiotis V Benos, Jacqueline Ho, John P Johnson, Michael B Butterworth
Journal of the American Society of Nephrology (Impact Factor: 8.99). 04/2014; http://dx. DO.org/I:10.1681/ASN.2013090931
Source: PubMed
ABSTRACT A role for microRNAs (miRs) in the physiologic regulation of sodium transport in the kidney has not been established. In this study, we investigated the potential of aldosterone to alter miR expression in mouse cortical collecting duct (mCCD) epithelial cells. Microarray studies demonstrated the regulation of miR expression by aldosterone in both cultured mCCD and isolated primary distal nephron principal cells.
Aldosterone regulation of the most significantly downregulated miRs, mmu-miR-335-3p, mmu-miR-290-5p, and mmu-miR-1983 was confirmed by quantitative RT-PCR. Reducing the expression of these miRs separately or in combination increased epithelial sodium channel (ENaC)-mediated sodium transport in mCCD cells, without mineralocorticoid supplementation. Artificially increasing the expression of these miRs by transfection with plasmid precursors or miR mimic constructs blunted aldosterone stimulation of ENaC transport.
Using a newly developed computational approach, termed ComiR, we predicted potential gene targets for the aldosterone-regulated miRs and confirmed ankyrin 3 (Ank3) as a novel aldosterone and miR-regulated protein.
A dual-luciferase assay demonstrated direct binding of the miRs with the Ank3-3′ untranslated region. Overexpression of Ank3 increased and depletion of Ank3 decreased ENaC-mediated sodium transport in mCCD cells. These findings implicate miRs as intermediaries in aldosterone signaling in principal cells of the distal kidney nephron.
2. Diagnostic Biomarker Status
A prospective study of the impact of serial troponin measurements on the diagnosis of myocardial infarction and hospital and 6-month mortality in patients admitted to ICU with non-cardiac diagnoses.
Marlies Ostermann, Jessica Lo, Michael Toolan, Emma Tuddenham, Barnaby Sanderson, Katie Lei, John Smith, Anna Griffiths, Ian Webb, James Coutts, John hambers, Paul Collinson, Janet Peacock, David Bennett, David Treacher
Critical care (London, England) (Impact Factor: 4.72). 04/2014; 18(2):R62. http://dx.doi.org/:10.1186/cc13818
Source: PubMed
ABSTRACT Troponin T (cTnT) elevation is common in patients in the Intensive Care Unit (ICU) and associated with morbidity and mortality. Our aim was to determine the epidemiology of raised cTnT levels and contemporaneous electrocardiogram (ECG) changes suggesting myocardial infarction (MI) in ICU patients admitted for non-cardiac reasons.
cTnT and ECGs were recorded daily during week 1 and on alternate days during week 2 until discharge from ICU or death. ECGs were interpreted independently for the presence of ischaemic changes. Patients were classified into 4 groups: (i) definite MI (cTnT >=15 ng/L and contemporaneous changes of MI on ECG), (ii) possible MI (cTnT >=15 ng/L and contemporaneous ischaemic changes on ECG), (iii) troponin rise alone (cTnT >=15 ng/L), or (iv) normal. Medical notes were screened independently by two ICU clinicians for evidence that the clinical teams had considered a cardiac event.
Data from 144 patients were analysed [42% female; mean age 61.9 (SD 16.9)]. 121 patients (84%) had at least one cTnT level >=15 ng/L. A total of 20 patients (14%) had a definite MI, 27% had a possible MI, 43% had a cTNT rise without contemporaneous ECG changes, and 16% had no cTNT rise. ICU, hospital and 180 day mortality were significantly higher in patients with a definite or possible MI.Only 20% of definite MIs were recognised by the clinical team. There was no significant difference in mortality between recognised and non-recognised events.At time of cTNT rise, 100 patients (70%) were septic and 58% were on vasopressors. Patients who were septic when cTNT was elevated had an ICU mortality of 28% compared to 9% in patients without sepsis. ICU mortality of patients who were on vasopressors at time of cTNT elevation was 37% compared to 1.7% in patients not on vasopressors.
The majority of critically ill patients (84%) had a cTnT rise and 41% met criteria for a possible or definite MI of whom only 20% were recognised clinically. Mortality up to 180 days was higher in patients with a cTnT rise.
Prognostic performance of high-sensitivity cardiac troponin T kinetic changes adjusted for elevated admission values and the GRACE score in an unselected emergency department population.
Moritz Biener, Matthias Mueller, Mehrshad Vafaie, Allan S Jaffe, Hugo A Katus,Evangelos Giannitsis
Clinica chimica acta; international journal of clinical chemistry (Impact Factor: 2.54). 04/2014; http://dx.doi.org/10.1016/j.cca.2014.04.007
Source: PubMed
ABSTRACT To test the prognostic performance of rising and falling kinetic changes of high-sensitivity cardiac troponin T (hs-cTnT) and the GRACE score.
Rising and falling hs-cTnT changes in an unselected emergency department population were compared.
635 patients with a hs-cTnT >99th percentile admission value were enrolled. Of these, 572 patients qualified for evaluation with rising patterns (n=254, 44.4%), falling patterns (n=224, 39.2%), or falling patterns following an initial rise (n=94, 16.4%). During 407days of follow-up, we observed 74 deaths, 17 recurrent AMI, and 79 subjects with a composite of death/AMI. Admission values >14ng/L were associated with a higher rate of adverse outcomes (OR, 95%CI:death:12.6, 1.8-92.1, p=0.01, death/AMI:6.7, 1.6-27.9, p=0.01). Neither rising nor falling changes increased the AUC of baseline values (AUC: rising 0.562 vs 0.561, p=ns, falling: 0.533 vs 0.575, p=ns). A GRACE score ≥140 points indicated a higher risk of death (OR, 95%CI: 3.14, 1.84-5.36), AMI (OR,95%CI: 1.56, 0.59-4.17), or death/AMI (OR, 95%CI: 2.49, 1.51-4.11). Hs-cTnT changes did not improve prognostic performance of a GRACE score ≥140 points (AUC, 95%CI: death: 0.635, 0.570-0.701 vs. 0.560, 0.470-0.649 p=ns, AMI: 0.555, 0.418-0.693 vs. 0.603, 0.424-0.782, p=ns, death/AMI: 0.610, 0.545-0.676 vs. 0.538, 0.454-0.622, p=ns). Coronary angiography was performed earlier in patients with rising than with falling kinetics (median, IQR [hours]:13.7, 5.5-28.0 vs. 20.8, 6.3-59.0, p=0.01).
Neither rising nor falling hs-cTnT changes improve prognostic performance of elevated hs-cTnT admission values or the GRACE score. However, rising values are more likely associated with the decision for earlier invasive strategy.
Troponin assays for the diagnosis of myocardial infarction and acute coronary syndrome: where do we stand?
Arie Eisenman
ABSTRACT: Under normal circumstances, most intracellular troponin is part of the muscle contractile apparatus, and only a small percentage (< 2-8%) is free in the cytoplasm. The presence of a cardiac-specific troponin in the circulation at levels above normal is good evidence of damage to cardiac muscle cells, such as myocardial infarction, myocarditis, trauma, unstable angina, cardiac surgery or other cardiac procedures. Troponins are released as complexes leading to various cut-off values depending on the assay used. This makes them very sensitive and specific indicators of cardiac injury. As with other cardiac markers, observation of a rise and fall in troponin levels in the appropriate time-frame increases the diagnostic specificity for acute myocardial infarction. They start to rise approximately 4-6 h after the onset of acute myocardial infarction and peak at approximately 24 h, as is the case with creatine kinase-MB. They remain elevated for 7-10 days giving a longer diagnostic window than creatine kinase. Although the diagnosis of various types of acute coronary syndrome remains a clinical-based diagnosis, the use of troponin levels contributes to their classification. This Editorial elaborates on the nature of troponin, its classification, clinical use and importance, as well as comparing it with other currently available cardiac markers.
Expert Review of Cardiovascular Therapy 07/2006; 4(4):509-14. http://dx.doi.org/:10.1586/14779072.4.4.509
Impact of redefining acute myocardial infarction on incidence, management and reimbursement rate of acute coronary syndromes.
Carísi A Polanczyk, Samir Schneid, Betina V Imhof, Mariana Furtado,Carolina Pithan, Luis E Rohde, Jorge P Ribeiro
ABSTRACT: Although redefinition for acute myocardial infarction (AMI) has been proposed few years ago, to date it has not been universally adopted by many institutions. The purpose of this study is to evaluate the diagnostic, prognostic and economical impact of the new diagnostic criteria for AMI. Patients consecutively admitted to the emergency department with suspected acute coronary syndromes were enrolled in this study. Troponin T (cTnT) was measured in samples collected for routine CK-MB analyses and results were not available to physicians. Patients without AMI by traditional criteria and cTnT > or = 0.035 ng/mL were coded as redefined AMI. Clinical outcomes were hospital death, major cardiac events and revascularization procedures. In-hospital management and reimbursement rates were also analyzed. Among 363 patients, 59 (16%) patients had AMI by conventional criteria, whereas additional 75 (21%) had redefined AMI, an increase of 127% in the incidence. Patients with redefined AMI were significantly older, more frequently male, with atypical chest pain and more risk factors. In multivariate analysis, redefined AMI was associated with 3.1 fold higher hospital death (95% CI: 0.6-14) and a 5.6 fold more cardiac events (95% CI: 2.1-15) compared to those without AMI. From hospital perspective, based on DRGs payment system, adoption of AMI redefinition would increase 12% the reimbursement rate [3552 Int dollars per 100 patients evaluated]. The redefined criteria result in a substantial increase in AMI cases, and allow identification of high-risk patients. Efforts should be made to reinforce the adoption of AMI redefinition, which may result in more qualified and efficient management of ACS.
International Journal of Cardiology 03/2006; 107(2):180-7. · 5.51 Impact Factor http://www.sciencedirect.com/science/article/pii/S0167527305005279
3. Biomedical Engineering
Safety and Efficacy of an Injectable Extracellular Matrix Hydrogel for Treating Myocardial Infarction
Sonya B. Seif-Naraghi, Jennifer M. Singelyn, Michael A. Salvatore, et al.
Sci Transl Med 20 February 2013 5:173ra25 http://dx.doi.org/10.1126/scitranslmed.3005503
Acellular biomaterials can stimulate the local environment to repair tissues without the regulatory and scientific challenges of cell-based therapies. A greater understanding of the mechanisms of such endogenous tissue repair is furthering the design and application of these biomaterials. We discuss recent progress in acellular materials for tissue repair, using cartilage and cardiac tissues as examples of application with substantial intrinsic hurdles, but where human translation is now occurring.
Acellular Biomaterials: An Evolving Alternative to Cell-Based Therapies
J. A. Burdick, R. L. Mauck, J. H. Gorman, R. C. Gorman,
Sci. Transl. Med. 2013; 5, (176): 176 ps4 http://stm.sciencemag.org/content/5/176/176ps4
Acellular biomaterials can stimulate the local environment to repair tissues without the regulatory and scientific challenges of cell-based therapies. A greater understanding of the mechanisms of such endogenous tissue repair is furthering the design and application of these biomaterials. We discuss recent progress in acellular materials for tissue repair, using cartilage and cardiac tissues as examples of applications with substantial intrinsic hurdles, but where human translation is now occurring.
Instructive Nanofiber Scaffolds with VEGF Create a Microenvironment for Arteriogenesis and Cardiac Repair
Yi-Dong Lin, Chwan-Yau Luo, Yu-Ning Hu, Ming-Long Yeh, Ying-Chang Hsueh, Min-Yao Chang, et al.
Sci Transl Med 8 August 2012; 4(146):ra109. http://dx.doi.org/ 10.1126/scitranslmed.3003841
Angiogenic therapy is a promising approach for tissue repair and regeneration. However, recent clinical trials with protein delivery or gene therapy to promote angiogenesis have failed to provide therapeutic effects. A key factor for achieving effective revascularization is the durability of the microvasculature and the formation of new arterial vessels. Accordingly, we carried out experiments to test whether intramyocardial injection of self-assembling peptide nanofibers (NFs) combined with vascular endothelial growth factor (VEGF) could create an intramyocardial microenvironment with prolonged VEGF release to improve post-infarct neovascularization in rats. Our data showed that when injected with NF, VEGF delivery was sustained within the myocardium for up to 14 days, and the side effects of systemic edema and proteinuria were significantly reduced to the same level as that of control. NF/VEGF injection significantly improved angiogenesis, arteriogenesis, and cardiac performance 28 days after myocardial infarction. NF/VEGF injection not only allowed controlled local delivery but also transformed the injected site into a favorable microenvironment that recruited endogenous myofibroblasts and helped achieve effective revascularization. The engineered vascular niche further attracted a new population of cardiomyocyte-like cells to home to the injected sites, suggesting cardiomyocyte regeneration. Follow-up studies in pigs also revealed healing benefits consistent with observations in rats. In summary, this study demonstrates a new strategy for cardiovascular repair with potential for future clinical translation.
Manufacturing Challenges in Regenerative Medicine
I. Martin, P. J. Simmons, D. F. Williams.
Sci. Transl. Med. 2014; 6(232): fs16. http://dx.doi.org/10.1126/scitranslmed.3008558
Along with scientific and regulatory issues, the translation of cell and tissue therapies in the routine clinical practice needs to address standardization and cost-effectiveness through the definition of suitable manufacturing paradigms.
Epilogue to Volume Four
Larry H Bernstein, MD, FCAP, Author and Curator, Volume Four, Co-Editor
Justin Pearlman, MD, PhD, FACC, Content Consultant for Series A: Cardiovascular Diseases
Aviva Lev-Ari, PhD, RN, Co-Editor of Volume Four and Editor-in-Chief, BioMed e-Series
This completes Chapter 4 in two parts on the most dynamic developments in the regulatory pathways guiding cardiovascular dynamics and function in health and disease. I have covered key features of these in two summaries, so I shall try to look further into important expected future directions and their anticipated implications.
1. Mechanisms of Disease
Omega-3 Index and Cardiovascular Health
Clemens von Schacky
Nutrients 2014; 6: 799-814;
http://www.mdpi.com/2072-6643/6/2/799
Signal Transduction: Akt Phosphorylates HK-II at Thr-473 and Increases Mitochondrial HK-II Association to Protect Cardiomyocytes
David J. Roberts, Valerie P. Tan-Sah, Jeffery M. Smith and Shigeki Miyamoto
J. Biol. Chem. 2013, 288:23798-23806. http://dx.doi.org/ 10.1074/jbc.M113.482026
Backgound: Hexokinase II binds to mitochondria and promotes cell survival.
Results: Akt phosphorylates HK-II but not the threonine 473 mutant. The phosphomimetic T473D mutant decreases its dissociation from mitochondria induced by G-6P and increases cell viability against stress.
Conclusion: Akt phosphorylates HK-II at Thr-473, resulting in increased mitochondrial HK-II and cell protection.
Significance: The Akt-HK-II signaling nexus is important in cell survival.
It has been demonstrated that an increased level of HK-II at mitochondria is protective and is increased by protective interventions but decreased under stress.
It has not been fully determined which molecular signals regulate the level of HK-II at mitochondria.
Thr-473 in HK-II is phosphorylated by Akt and this phosphorylation leads to increases in mitochondrial HK-II binding through inhibition of G-6P-dependent dissociation, conferring resistance to oxidative stress (Fig. 7).
Overexpression of WTHK-II increases mitochondrial HK-II and confers protection against hydrogen peroxide, which is enhanced significantly in HK-II T473D-expressing cells, whereas NHK-II, lacking the ability to bind to mitochondria, does not confer protection. Conversely, mitochondrial HK-II from mitochondria (Fig.6, A and B) inhibits the IGF-1-mediated increase in mitochondrial HK-II and cellular protection. Similar dose-dependent curves were obtained in mitochondrial HK-II against stress (15–25).
Gene Expression and Genetic Variation in Human Atria
Honghuang Lin PhD, Elena V. Dolmatova MD, Michael P. Morley, PhD, Kathryn L. Lunetta PhD, David D. McManus MD, ScM, et al.
Heart Rhythm 2013 http://dx.doi.org/10.1016/j.hrthm.2013.10.051
Background— The human left and right atria have different susceptibilities to develop atrialfibrillation (AF). However, the molecular events related to structural and functional changes that
enhance AF susceptibility are still poorly understood.
Objective— To characterize gene expression and genetic variation in human atria.
Results— We found that 109 genes were differentially expressed between left and right atrial tissues. A total of 187 and 259 significant cis-associations between transcript levels and genetic
variants were identified in left and right atrial tissues, respectively. We also found that a SNP at a known AF locus, rs3740293, was associated with the expression of MYOZ1 in both left and right
atrial tissues.
Conclusion— We found a distinct transcriptional profile between the right and left atrium, and extensive cis-associations between atrial transcripts and common genetic variants. Our results
implicate MYOZ1 as the causative gene at the chromosome 10q22 locus for AF.
Long-Term Caspase Inhibition Ameliorates Apoptosis, Reduces Myocardial Troponin-I Cleavage, Protects Left Ventricular Function, and Attenuates Remodeling in Rats With Myocardial Infarction
Y. Chandrashekhar, Soma Sen, Ruth Anway, Allan Shuros, Inder Anand,
J Am Col Cardiol 2004; 43(2) http://dx.doi.org/10.1016/j.jacc.2003.09.026
This study was designed to evaluate whether in vivo caspase inhibition can prevent myocardial contractile protein degradation, improve myocardial function, and attenuate ventricular remodeling.
Apoptosis is thought to play an important role in the development and progression of heart failure (HF) after a myocardial infarction (MI). However, it is not known whether inhibiting apoptosis can attenuate left ventricular (LV) remodeling and minimize systolic dysfunction.
A 28-day infusion of caspase inhibitor was administeredimmediately after an anterior MI. In addition, five sham-operated rats given the caspase inhibitor were compared with 17 untreated sham-operated animals to study effects in non-MI rats. Left ventricular function, remodeling parameters, and hemodynamics were studied four weeks later. Myocardial caspase 3 activation and troponin-I contractile protein cleavage were studied in the non-infarct, remote LV myocardium using Western blots. Apoptosis was assessed using immunohistochemistry for activated caspase-positive cells as well as the TUNEL method. Collagen volume was estimated using morphometry.
Caspase inhibition reduced myocardial caspase 3 activation. This was accompanied by less cleavage of troponin-I, an important component of the cardiac contractile apparatus, and fewer apoptotic cardiomyocytes. Furthermore, caspase inhibition reduced LV-weight-to- body-weight ratio, decreased myocardial interstitial collagen deposition, attenuated LV remodeling, and better preserved LV systolic function after MI.
Caspase inhibition, started soon after MI and continued for four weeks, preserves myocardial contractile proteins, reduces systolic dysfunction, and attenuates ventricular remodeling.
These findings may have important therapeutic implications in post-MI HF. J Am Col Cardiol 2004;43:295–301)
Precardiac deletion of Numb and Numblike reveals renewal of cardiac progenitors
Lincoln T Shenje, Peter P Rainer , Gun-sik Cho , Dong-ik Lee , Weimin Zhong , Richard P Harvey , David A Kass , Chulan Kwon *, et al.
eLife 2014. http://dx.doi.org/10.7554/eLife.02164.001
Cardiac progenitor cells (CPCs) must control their number and fate to sustain the rapid heart growth during development, yet the intrinsic factors and environment governing these processes remain unclear. Here, we show that deletion of the ancient cell-fate regulator Numb (Nb) and its homologue Numblike (Nbl) depletes CPCs in second pharyngeal arches (PA2s) and is associated with an atrophic heart. With histological, fow cytometric and functional analyses, we fnd that CPCs remain undifferentiated and expansive in the PA2, but differentiate into cardiac cells as they exit the arch. Tracing of Nb- and Nbl-defcient CPCs by lineage-specifc mosaicism reveals that the CPCs normally populate in the PA2, but lose their expansion potential in the PA2. These fndings demonstrate that Nb and Nbl are intrinsic factors crucial for the renewal of CPCs in the PA2 and
that the PA2 serves as a microenvironment for their expansion.
2. Diagnostics and Risk Assessment
Classical and Novel Biomarkers for Cardiovascular Risk Prediction in the United States
Aaron R. Folsom
J Epidemiol 2013;23(3):158-162 http://dx.doi.org/10.2188/jea.JE20120157
Cardiovascular risk prediction models based on classical risk factors identified in epidemiologic cohort studies are useful in primary prevention of cardiovascular disease in individuals. This article briefly reviews aspects of
cardiovascular risk prediction in the United States and efforts to evaluate novel risk factors. Even though many novel risk markers have been found to be associated with cardiovascular disease, few appear to improve risk prediction
beyond the powerful, classical risk factors. A recent US consensus panel concluded that clinical measurement of certain novel markers for risk prediction was reasonable, namely,
- hemoglobin A1c (in all adults),
- microalbuminuria (in patients with hypertension or diabetes), and
- C-reactive protein,
- lipoprotein-associated phospholipase,
- coronary calcium,
- carotid intima-media thickness, and
- ankle/brachial index (in patients deemed to be at intermediate cardiovascular risk, based on traditional risk factors).
Diagnostic accuracy of NT-proBNP ratio (BNP-R) for early diagnosis of tachycardia-mediated cardiomyopathy: a pilot study
Amir M. Nia, Natig Gassanov, Kristina M. Dahlem, Evren Caglayan, Martin Hellmich, et al.
Clin Res Cardiol (2011) 100:887–896 http://dx.doi.org/10.1007/s00392-011-0319-y
Tachycardia-mediated cardiomyopathy (TMC) occurs as a consequence of prolonged high heart rate due to ventricular and supraventricular tachycardia. In animal models, rapid pacing induces severe biventricular remodeling with dilation and dysfunction [7]. On a cellular basis, cardiomyocytes exert fundamental morphological and functional roles.
When heart failure and tachycardia occur simultaneously, a useful diagnostic tool for early discrimination of patients with benign tachycardia-mediated cardiomyopathy (TMC) versus major structural heart disease (MSHD) is not available. Such a tool is required to prevent unnecessary and wearing diagnostics in patients with reversible TMC. Moreover, it could lead to early additional diagnostics and therapeutic approaches in patients with MSHD.
A total of 387 consecutive patients with supraventricular arrhythmia underwent assessment. Of these patients, 40 fulfilled the inclusion criteria
with a resting heart rate C100 bpm and an impaired left ventricular ejection fraction \40%. In all patients, successful electrical cardioversion was performed. At baseline, day 1 and weekly for 4 weeks, levels of NT-proBNP and echocardiographic parameters were evaluated.
NT-proBNP ratio (BNP-R) was calculated as a quotient of baseline NT-proBNP/follow-up NT-proBNP. After 4 weeks, cardiac catheterization was performed to identify patients with a final diagnosis of TMC versus MSHD.
Initial NT-proBNP concentrations were elevated and consecutively decreased after cardioversion in all patients studied. The area under the ROC curve for BNP-R to detect TMC was 0.90 (95% CI 0.79–1.00; p \ 0.001) after 1 week and 0.995 (95% CI 0.99–1.00; p \ 0.0001) after 4 weeks. One week after cardioversion already, a BNP-R cutoff C2.3 was useful for TMC diagnosis indicated by an accuracy of 90%, sensitivity of 84% and specificity of 95%.
BNP-R was found to be highly accurate for the early diagnosis of TMC.
Omega-3 Index and Cardiovascular Health
Clemens von Schacky, Nutrients 2014; 6: 799-814; http://dx. doi.org/10.3390/nu602099
Fish, marine oils, and their concentrates all serve as sources of the two marine omega-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), as do some products from algae.
To demonstrate an effect of EPA + DHA on heart health, a number of randomized, controlled intervention studies with clinical endpoints like overall mortality or a combination of adverse cardiac events were conducted in populations with elevated cardiovascular risk. One early intervention study with oily fish, rich in EPA + DHA, and some early studies with fish oil or fish oil concentrate or even purified EPA at doses ranging between 0.9 and 1.8 g/day indeed demonstrated effects in terms of fewer sudden cardiac deaths, fatal or non-fatal myocardial infarctions, or a combination of adverse cardiac events.
Recent meta-analyses found no significant benefits on total mortality, cardiovascular mortality, and other adverse cardiac or cardiovascular events [13–18]. This is in contrast to findings in epidemiologic studies, where intake of EPA + DHA had been found to correlate generally with an up to 50% lower incidence of adverse cardiac events [18,19], and in even sharper contrast to epidemiologic studies based on levels of EPA + DHA, demonstrating e.g., a 10-fold lower incidence of sudden cardiac death associated with high levels of the fatty acids, as compared to low levels.
This seemingly contradictory evidence has led the American Heart Association to recommend “omega-3 fatty acids from fish or fish oil capsules (1 g/day) for cardiovascular disease risk reduction” for secondary prevention, whereas the European Society for Cardiology recommends “Fish at least twice a week, one of which to be oily fish”, but no supplements for cardiovascular prevention.
A similar picture emerges for atrial fibrillation: In epidemiologic studies, consumption of EPA + DHA or higher levels of EPA + DHA were associated with lower risk for developing atrial fibrillation, while intervention studies found no effect. Pertinent guidelines do not mention EPA + DHA. A similar picture also emerges for severe ventricular rhythm disturbances.
Why is it that trial results are at odds with results from epidemiology? What needs to be done to better translate the epidemiologic findings into trial results? The current review will try to shed some light on this issue, with a special consideration of the Omega-3 Index.
Recent large trials with eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) in the cardiovascular field did not demonstrate a beneficial effect in terms of reductions of clinical endpoints like
- total mortality,
- sudden cardiac arrest or
- other major adverse cardiac events.
Pertinent guidelines do not uniformly recommend EPA + DHA for cardiac patients. In contrast,
- in epidemiologic findings, higher blood levels of EPA + DHA were consistently associated with a lower risk for the endpoints mentioned.
The following points argue for the use of erythrocytes: erythrocyte fatty acid
composition has a low biological variability, erythrocyte fat consists almost exclusively of phospholipids, erythrocyte fatty acid composition reflects tissue fatty acid composition, pre-analytical stability, and other points. In 2004, EPA + DHA in erythrocyte fatty acids were defined as the Omega-3 Index and suggested as a risk factor for sudden cardiac death [39]. Integral to the definition was a specific and standardized analytical procedure, conforming the quality management routinely implemented in the field of clinical chemistry.
The laboratories adhering to the HS-Omega-3 Index methodology perform regular proficiency testing, as mandated in routine Clinical Chemistry labs. So far, the HS-Omega-3 Index is the only analytical procedure used in several laboratories. A standardized analytical procedure is a prerequisite to generate the data base necessary to transport a laboratory parameter from research into clinical routine. Moreover, standardization of the analytical procedure is the first important criterion for establishing a new biomarker for cardiovascular risk set forth by the American Heart Association and the US Preventive Services Task Force.
Because of low biological and analytical variability, a standardized analytical procedure, a large database and for other reasons,
- blood levels of EPA + DHA are frequently assessed in erythrocytes, using the HS-Omega-3 Index methodology.
Table 1. Mean HS-Omega-3 Index values in various populations, Mean (±standard deviation (SD)). Please note that in every population studied, a lower value was found to be associated with a worse condition than a higher value. References are given, if not, unpublished, n = number of individuals measured.
All levels of fatty acids are determined by the balance of substance entering the body and those leaving the body. Neither a recent meal, even if rich in EPA + DHA, nor severe cardiac events altered the HS-Omega-3 Index. However, while long-term intake of EPA + DHA, e.g., as assessed with food questionnaires, was the main predictor of the HS-Omega-3 Index, long-term intake explained only 12%–25% of its variability. A hereditary component of 24% exists. A number of other factors correlated positively (+) or negatively (−), like age (+), body mass index (−), socioeconomic status (+), smoking (−), but no other conventional cardiac risk factors. More factors determining the level of the HS-Omega-3 Index, especially regarding efflux remain to be defined. Therefore, it is impossible to predict the HS-Omega-3 Index in an individual, as it is impossible to predict the increase in the HS-Omega-3 Index in an individual in response to a given dose of EPA + DHA. In Table 2, current evidence is presented on the relation of the HS-Omega-3 Index to CV events.
The HS-Omega-3 Index has made it possible to reclassify individuals from intermediate cardiovascular risk into the respective high risk and low risk strata, the third criterion for establishing a new biomarker for CV risk.
A low Omega-3 Index fulfills the current criteria for a novel cardiovascular risk factor.
Increasing the HS-Omega-3 Index by increased intake of EPA + DHA in randomized controlled trials improved a number of surrogate parameters for cardiovascular risk:
- heart rate was reduced,
- heart rate variability was increased,
- blood pressure was reduced,
- platelet reactivity was reduced,
- triglycerides were reduced,
- large buoyant low-density lipoprotein (LDL)-particles were increased and
- small dense LDL-particles were reduced,
- large buoyant high-density lipoproteins (HDL)2 were increased,
- very low-density lipoprotein (VLDL1) + 2 was reduced,
- pro-inflammatory cytokines (e.g., tumor necrosis factor alpha, interleukin-1β, interleukins-6,8,10 and monocyte chemoattractant protein-1) were reduced,
- anti-inflammatory oxylipins were increased.
Importantly, in a two-year randomized double-blind angiographic intervention trial, increased erythrocyte EPA + DHA
- reduced progression and increased regression of coronary lesions, an intermediate parameter.
Taken together, increasing the HS-Omega-3 Index improved surrogate and intermediate parameters for cardiovascular events. A large intervention trial with clinical endpoints based on the HS-Omega-3 Index remains to be conducted. Therefore, the fourth criterion, proof of therapeutic consequence of determining the HS-Omega- Index, is only partially fulfilled.
Neutral results of intervention trials can be explained by issues of bioavailability and trial design that surfaced after the trials were initiated.
In the future, incorporating the Omega-3 Index into trial designs by
- recruiting participants with a low Omega-3 Index and
- treating them within a pre-specified target range (e.g., 8%–11%),
- will make more efficient trials possible and
- provide clearer answers to the questions asked than previously possible.
3. Stem Cells and Regenerative Biology
Adult Stem Cells Reverse Muscle Atrophy In Elderly Mice http://www.science20.com/profile/news_staff
Bioengineers at the University of California, Berkeley in a new study published in Nature say they have identified two key regulatory pathways that control how well adult stem cells repair and replace damaged tissue. They then tweaked how those stem cells reacted to those biochemical signals to revive the ability of muscle tissue in old mice to repair itself nearly as well as the muscle in the mice’s much younger counterparts. Irina Conboy, an assistant professor of bioengineering and an investigator at the Berkeley Stem Cell Center and at the California Institute for Quantitative Biosciences (QB3), led the research team conducting this study. Because the findings relate to adult stem cells that reside in existing tissue, this approach to rejuvenating degenerating muscle eliminates the ethical and medical complications associated with transplanting tissues grown from embryonic stem cells. The researchers focused on
- the interplay of two competing molecular pathways that control the stem cells,
which sit next to the mature, differentiated cells that make up our working body parts. When the mature cells are damaged or wear out, the stem cells are called into action to begin the process of rebuilding.
“We don’t realize it, but as we grow our bodies are constantly being remodeled,” said Conboy. “We are constantly falling apart, but we don’t notice it much when we’re young because we’re always being restored. As we age, our stem cells are prevented, through chemical signals, from doing their jobs.” The good news, the researchers said, is that
- the stem cells in old tissue are still ready and able to perform their regenerative function
- if they receive the appropriate chemical signals.
Studies have shown that when old tissue is placed in an environment of young blood, the stem cells behave as if they are young again. “Conversely, we have found in a study published last year that even young stem cells rapidly age when placed among blood and tissue from old mice,” said Carlson, who will stay on at UC Berkeley to expand his work on stem cell engineering.
- Adult stem cells have a receptor called Notch that, when activated,
- tells them that it is time to grow and divide
- stem cells also have a receptor for the protein TGF-beta
- that sets off a chain reaction activatingthemoleculepSmad3 and
- ultimately producing cyclin-dependent kinase (CDK) inhibitors, which regulate the cell’s ability to divide.
- activated Notch competes with activated pSmad3 for
- binding to the regulatory regions of the same CDK inhibitors in the stem cell
“We found that Notch is capable of physically kicking off pSmad3 from the promoters for the CDK inhibitors within the stem cell’s nucleus, which tells us that a precise manipulation of the balance of these pathways would allow the ability to control stem cell responses.” Notch and TGF-beta are well known in molecular biology, but Conboy’s lab is the first to connect them to the process of aging, and the first to show that they act in opposition to each other within the nucleus of the adult stem cell. Aging and the inevitable march towards death are, in part, due to the progressive decline of Notch and the increased levels of TGF-beta , producing a one-two punch to the stem cell’s capacity to effectively rebuild the body, the researchers said.
The researchers disabled the “aging pathway” that tells stem cells to stop dividing by using an established method of RNA interference that reduced levels of pSmad3. The researchers then examined the muscle of the different groups of mice one to five days after injury to compare how well the tissue repaired itself. As expected,
- muscle tissue in the young mice easily replaced damaged cells with new, healthy cells. In contrast,
- the areas of damaged muscle in the control group of old mice were characterized by fibroblasts and scar tissue. However,
- muscles in the old mice whose stem cell “aging pathway”had been dampened showed levels of cellular regeneration that were
- comparable to their much younger peers, and that were 3 to 4 times greater than those of the group of “untreated” old mice.
Adult Stem Cells To Repair Damaged Heart Muscle
http://www.science20.com/profile/news_staff
In the first trial of its kind in the world, 60 patients who have recently suffered a major heart attack will be injected with selected stem cells from their own bone marrow during routine coronary bypass surgery. The Bristol trial will test
- whether the stem cells will repair heart muscle cells damaged by the heart attack,
- by preventing late scar formation and hence impaired heart contraction.
“ Cardiac stem cell therapy aims to repair the damaged heart as it has the potential to replace the damaged tissue.” We have elected to use a very promising stem cell type selected from the patient’s own bone marrow. This approach ensures no risk of rejection or infection. It also gets around the ethical issues that would result from use of stem cells from embryonic or foetal tissue.
In this trial (known as TransACT), all patients will have bone marrow harvested before their heart operation. Then either stem cells from their own bone marrow or a placebo will be injected into the patients’ damaged hearts during routine coronary bypass surgery. The feasibility and safety of this technique has already been demonstrated. As a result of the chosen double blind placebo-controlled design, neither the patients nor the surgeon knows whether the patient is going to be injected with stem cells or placebo. This ensures that results are not biased in any way, and is the most powerful way to prove whether or not the new treatment is effective.
Research of Stem Cells Repair Damaged Heart
By Kelvinlew Minhan | March 26th 2008
Under highly specific growth conditions in laboratory culture dishes, stem cells
- can be coaxed into developing as new cardiomyocytes and vascular endothelial cells (Kirschstein and Skirboll, 2001).
Discoveries that have triggered the interest in the application of adult stem cells to heart muscle repair in animal models have been made by researchers in the past few years (Kirschstein and Skirboll, 2001). One study demonstrated that cardiac tissue can be regenerated in the mouse heart attack model through the introduction of adult stem cells from mouse bone marrow (Kirschstein and Skirboll, 2001). These cells were transplanted into the marrow of irradiated mice approximately 10 weeks before the recipient mice were subjected to heart attack thru tying off different major heart blood vessel, the left anterior descending (LAD) coronary artery. The survival rate was 26 percent at two to four weeks after the induced cardiac injury (Kirschstein and Skirboll, 2001). Another study of the region surrounding the damaged tissue in surviving mice showed the presence of donor-derived cardiomyocytes and endothelial cells (Kirschstein and Skirboll, 2001).
- the mouse hematopoietic stem cells transplanted into the bone marrow had migrated to the border part of the damaged area, and differentiated into several types of tissue for cardiac repair.
Regenerating heart tissue through stem cell therapy
http://www.mayo.edu/research/discoverys-edge/regenerating-heart-tissue-stem-cell-therapy
Summary
A groundbreaking study on repairing damaged heart tissue through stem cell therapy has given patients hope that they may again live active lives. An international team of Mayo Clinic researchers and collaborators has done it by discovering a way to regenerate heart tissue.
- stem cells are harvested from a patient’s bone marrow.
- undergo a laboratory treatment that guides them into becoming cardiac cells,
- which are then injected into the patient’s heart in an effort to grow healthy heart tissue.
Creating a heart repair kit
- they simulated the effects of eliminating proteins one by one from the process of heart development.
- That method yielded about 25 proteins.
- The team then pared that number down to 8 proteins that their data indicated were essential.
“Ihis newprocessofcardiopoiesiswas achieved in 100 percent of cases, with a very good safety profile,” Dr.Terzic says. “We are enabling the heart toregainitsinitial structure and function,” Dr.Terzic says, “and we will not stop here.” The clinicaltrialfindingsareexpectedto be published in the Journal of the American College of Cardiology in 2013. Meanwhile, research to improve the injection process and effectiveness is underway.
Stem Cells from Humans Repair Heart Damage in Monkeys
GEN News Highlights May1, 2014
Molecule Implicated In Leukemia Also Important In Muscle Repair
http://www.science20.com/profile/news_staff
The study shows that immature muscle cells require the molecule, called miR-29, to become mature, and that
4. Drug Discovery
GPCR Insights Brighten Drug Discovery Outlook
GEN Apr 15, 2014 (Vol. 34, No. 8)
Recent years have seen major advances in understanding the structure-function relationships of G protein-coupled receptors (GPCRs). This large superfamily of transmembrane receptors comprises over 800 members in humans.
GPCRs regulate a wide variety of physiological processes including
- sensation (vision, taste, and smell),
- growth,
- hormone responses, and
- regulation of the immune and
- autonomic nervous systems.
Their involvement in multiple disease pathways makes GPCRs attractive targets for drug discovery efforts.
These multifaceted proteins will be the subject of “GPCR Structure, Function and Drug Discovery,” a Global Technology Community conference scheduled to take place May 22–23 in Boston. The conference is expected to cover a broad range of topics including biased signaling, membrane protein structures, GPCR signaling dynamics, computational approaches to disease.
According to Bryan Roth, M.D., Ph.D., Michael Hooker Distinguished Professor at the University of North Carolina, Chapel Hill,
- drugs that can selectively target various downstream GPCR pathways hold the most promise.
Dr. Roth’s laboratory studies approximately 360 different GPCRs with therapeutic potential using massively parallel screening methods. His research focuses on “functional selectivity,” which he describes as
- “the ligand-dependent selectivity for certain signal transduction pathways in one and the same receptor.”
Dr. Roth notes that structural data have demonstrated that GPCRs exist in multiple conformations: “The structures of the 5-hydroxytryptamine 2B receptor and the recent high-resolution delta-opioid receptor structure have provided evidence for conformational rearrangements that contribute to functional selectivity.” Drugs that take advantage of this selectivity by preferentially stabilizing certain conformations may have unique therapeutic utility.
“Generally, we look at G protein versus arrestin-based signaling, although it’s also possible to examine how drugs activate one G protein-mediated signaling pathway versus another.
- β-Arrestins constitute a major class of intracellular scaffolding proteins that regulate GPCR signaling by preventing or enhancing the binding of GPCRs to intracellular signaling molecules. Laura Bohn, Ph.D., associate professor at Scripps Florida, studies the roles that β-arrestins play in GPCR-mediated signaling.
- a particular β-arrestin can play multiple, tissue-specific roles—shutting down the signaling of a receptor in one tissue while activating signaling in another.
- different ligands can direct GPCR signaling to different effectors, which could result in different physiological effects,” comments Dr. Bohn. “Our challenge is in determining what signaling pathways to harness to promote certain effects, while avoiding others.”
Using Designer Proteins
The multifunctional signaling abilities of β-arrestins has prompted large-scale study of their properties. Vsevolod Gurevich, Ph.D., professor of pharmacology at Vanderbilt University, studies
- the structure,
- function, and
- biology of arrestin proteins.
β-arrestins have three main functions.
- First, they prevent the coupling of GPCRs to G proteins, thereby blocking further G protein-mediated signaling (a process known as desensitization).
- Second, the binding of a GCPR releases the β-arrestin’s carboxy-terminal “tail” and promotes internalization of the receptor.
- Third, receptor-bound β-arrestins bind other signaling proteins, resulting in a second wave of arrestin-mediated signaling.
Dr. Gurevich’s laboratory studies β-arrestin biology through the use of three types of specially designed mutants—
- enhanced phosphorylation-dependent,
- receptor-specific, and
- signaling-biased mutants.
an enhanced mutant of visual β-arrestin-1 partially compensates for defects of rhodopsin phosphorylation in vivo,
“Several congenital disorders are caused by mutant GPCRs that cannot be normally phosphorylated because they have lost GPCR kinase (GRK) sites. Enhanced super-active arrestins have the potential to compensate for these defects, bringing the signaling closer to normal.”
- Dr. Gurevich explains the strategy involved in creating designer β-arrestins: “We identify residues critical for individual β-arrestin functions by mutagenesis, using limited structural information as a guide.
- We also work on getting more structural information. In collaboration with different crystallographers, we solved the crystal structures of all four vertebrate β-arrestin subtypes in the basal state, as well as the structure of the arrestin-1-rhodopsin complex.”
- Dr. Gurevich believes that designer β-arrestins “are the next step in research and therapy, moving way beyond what small molecules can achieve.
- The difference in capabilities between redesigned signaling proteins, including β-arrestins, and conventional small molecule drugs is about the same as that between airplanes and horse-driven carriages.”
- Dr. Gurevich observes that redesigned signaling proteins face considerable obstacles in terms of gene delivery, but that the efforts are worth it. “Using designer signaling proteins, we can tell the cell what to do in a language it cannot disobey,” asserts Dr. Gurevich.
Synthesis and Antihypertensive Screening of Novel Substituted 1,2- Pyrazoline Sulfonamide Derivatives
Avinash M. Bhagwat , Anilchandra R. Bha , Mahesh S. Palled , Anand P. Khadke , Anuradha M. Patil, et al.
Am. J. PharmTech Res. 2014; 4(2). http://www.ajptr.com/
Angiotensin II receptor antagonists, also known as angiotensin receptor blockers , AT1-receptor antagonists or sartans, are a group of pharmaceuticals which modulate the renin-angiotensin-aldosterone system. Their main use is in hypertension, diabetic nephropathy and congestiveheart failure. These substances are AT1-receptor antagonists which
- block the activationof angiotensin II AT1 receptors.
Blockade of AT1 receptors directly causes
1 vasodilation,
2 reduces secretion of vasopressin,
3 reduces production and secretion of aldosterone, amongst other actions –
4 the combined effect of which is reduction of blood pressure.
Irbesartan is a safe and effectiveangiotensin II receptor antagonist with an affinity for the AT1 receptor that is more than 8,500times greater than its affinity for AT2 receptor. This agent has a higher bioavailability (60-80%) than other drugs in its class . In both Losartan and Irbesartan structures imidazole moiety is being present. A structure analog of losartan and Irbesartan are designed by incorporating the heterocycles like pyrazoline group. We felt it would be interesting to explore the possibilities of 1,2-pyrazoline derivatives for Angiotensin II receptor antagonistic activity.
The Irbesartan structure was a modified Losartan structure, which had all the identity of a Losartan molecule but with groups that would fit the hydrophobic cavity with a tetramethylene group and an alkyl side chain that would fit in the pocket in the AT1 receptor. The hydroxyl methyl group of Losartan being replaced with carbonyl group of Irbesartan. With a view to introduce a hydrogen bonding interaction with AT1 receptor, these structures were further modified with a view of retaining both hydrogen bonding characteristics and as well as lipophilic groups. Losartan and Irbesartan structure contains a diphenyl molecule & imidazole ring.
In Losartan and Irbesartan diphenyl molecule is attached to the nitrogen of the imidazole ring. It is interesting to to see the activity of compounds containing two phenyl rings attached at two different positions namely3,5 position of 1, 2-pyrazoline ring. The sulphonamide derivatives known for its diuretics activity which reduces renal hypertension. We use to synthesize sulphonamide and pyrazoline in one molecule to check its possible Angiotensin II receptor antagonist property. For this reason chalcones were synthesized reacted with hydrazine hydrate to yield the corresponding 1,2-pyrazoline derivatives which further condensed with sulphanilamide and formaldehyde by mannich condensation reaction.
Acute Toxicity Study (LD50)
This study was carried out in order to establish the therapeutic and toxic doses of the newly synthesized 1,2 pyrazoline derivatives. To establish LD50 of these compounds the method described by Miller & Tainter was employed.
Leave a Reply